QUARTERLY REPORT

Q3 FY2024 — Quarterly report (Form 10-Q)

Q3 FY2024PDF · 39 pages509 KB
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark one)
x True QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the Quarterly Period Ended March 31, 2024
OR
o False TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from 	to
THE PROCTER & GAMBLE COMPANY
(Exact name of registrant as specified in its charter)
Ohio 	OH 	1-434 	31-0411980
(State of Incorporation) 	(Commission File Number) 	(I.R.S. Employer Identification Number)
One Procter & Gamble Plaza 	Cincinnati 	OH
One Procter & Gamble Plaza, Cincinnati, Ohio 	45202
(Address of principal executive offices) 	(Zip Code)
(513) 983-1100
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 	Trading Symbol 	Name of each exchange on which registered
Common Stock, without Par Value 	PG 	NYSE
0.500% Notes due 2024 	PG24A 	NYSE
0.625% Notes due 2024 	PG24B 	NYSE
1.375% Notes due 2025 	PG25 	NYSE
0.110% Notes due 2026 	PG26D 	NYSE
3.250% EUR Notes due 2026 	PG26E 	NYSE
4.875% EUR Notes due May 2027 	PG27A 	NYSE
1.200% Notes due 2028 	PG28 	NYSE
1.250% Notes due 2029 	PG29B 	NYSE
1.800% Notes due 2029 	PG29A 	NYSE
6.250% GBP Notes due January 2030 	PG30 	NYSE
0.350% Notes due 2030 	PG30C 	NYSE
0.230% Notes due 2031 	PG31A 	NYSE
3.250% EUR Notes due 2031 	PG31B 	NYSE
5.250% GBP Notes due January 2033 	PG33 	NYSE
1.875% Notes due 2038 	PG38 	NYSE
0.900% Notes due 2041 	PG41 	NYSE
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter)
during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of
"large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer 	þ 	Accelerated filer 	¨
Non-accelerated filer 	¨ 	Smaller reporting company 	¨ 	False
Emerging growth company 	¨ 	False
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No þ False
There were 2,360,135,282 shares of Common Stock outstanding as of March 31, 2024.

-- 1 of 39 --

FORM 10-Q TABLE OF CONTENTS 	Page
PART I 	Item 1. 	Financial Statements 	1
Consolidated Statements of Earnings 	1
Consolidated Statements of Comprehensive Income 	1
Consolidated Balance Sheets 	2
Consolidated Statements of Shareholders' Equity 	3
Consolidated Statements of Cash Flows 	5
Notes to Consolidated Financial Statements 	6
Note 1: Basis of Presentation 	6
Note 2: New Accounting Pronouncements and Policies 	6
Note 3: Segment Information 	6
Note 4: Goodwill and Intangible Assets 	7
Note 5: Earnings Per Share 	9
Note 6: Share-Based Compensation and Postretirement Benefits 	9
Note 7: Risk Management Activities and Fair Value Measurements 	10
Note 8: Accumulated Other Comprehensive Income/(Loss) 	11
Note 9: Commitments and Contingencies 	11
Note 10: Supplier Finance Programs 	12
Note 11: Restructuring Program 	12
Item 2. 	Management's Discussion and Analysis of Financial Condition and Results of Operations 	13
Item 3. 	Quantitative and Qualitative Disclosures About Market Risk 	29
Item 4. 	Controls and Procedures 	29
PART II 	Item 1. 	Legal Proceedings 	29
Item 1A. 	Risk Factors 	30
Item 2. 	Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities 	30
Item 5. 	Other Information 	30
Item 6. 	Exhibits 	31
Signature 	31

-- 2 of 39 --

The Procter & Gamble Company 1
PART I. FINANCIAL INFORMATION
Item 1. 	Financial Statements
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF EARNINGS
Three Months Ended March 31 	Nine Months Ended March 31
Amounts in millions except per share amounts 	2024 	2023 	2024 	2023
NET SALES 	$ 	20,195 $ 	20,068 $ 	63,507 $ 	61,453
Cost of products sold 	9,855 	10,404 	30,500 	32,147
Selling, general and administrative expense 	5,880 	5,416 	17,006 	15,334
Indefinite-lived intangible asset impairment charge 	— 	— 	1,341 	—
OPERATING INCOME 	4,460 	4,248 	14,660 	13,972
Interest expense 	(233) 	(222) 	(705) 	(516)
Interest income 	104 	83 	366 	191
Other non-operating income, net 	260 	179 	570 	473
EARNINGS BEFORE INCOME TAXES 	4,592 	4,288 	14,891 	14,120
Income taxes 	812 	864 	3,061 	2,774
NET EARNINGS 	3,781 	3,424 	11,830 	11,346
Less: Net earnings attributable to noncontrolling interests 	27 	27 	88 	77
NET EARNINGS ATTRIBUTABLE TO PROCTER & GAMBLE 	$ 	3,754 $ 	3,397 $ 	11,742 $ 	11,269
NET EARNINGS PER COMMON SHARE
Basic 	$ 	1.56 $ 	1.41 $ 	4.89 $ 	4.67
Diluted 	$ 	1.52 $ 	1.37 $ 	4.75 $ 	4.53
Basic net earnings per common share and Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Three Months Ended March 31 	Nine Months Ended March 31
Amounts in millions 	2024 	2023 	2024 	2023
NET EARNINGS 	$ 	3,781 $ 	3,424 $ 	11,830 $ 	11,346
OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX
Foreign currency translation 	(211) 	259 	(128) 	(74)
Unrealized gains/(losses) on investment securities 	— 	1 	(2) 	(2)
Unrealized gains/(losses) on defined benefit postretirement plans 	7 	(19) 	(23) 	(8)
TOTAL OTHER COMPREHENSIVE INCOME/(LOSS), NET OF TAX 	(204) 	241 	(153) 	(84)
TOTAL COMPREHENSIVE INCOME 	3,577 	3,665 	11,677 	11,262
Less: Total comprehensive income attributable to noncontrolling interests 	26 	28 	85 	70
TOTAL COMPREHENSIVE INCOME ATTRIBUTABLE TO PROCTER & GAMBLE 	$ 	3,551 $ 	3,637 $ 	11,592 $ 	11,192
(1)
(1)
See accompanying Notes to Consolidated Financial Statements.

-- 3 of 39 --

2 The Procter & Gamble Company
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
Amounts in millions 	March 31, 2024 	June 30, 2023
Assets
CURRENT ASSETS
Cash and cash equivalents 	$ 	6,828 $ 	8,246
Accounts receivable 	6,124 	5,471
INVENTORIES
Materials and supplies 	1,676 	1,863
Work in process 	971 	956
Finished goods 	4,431 	4,254
Total inventories 	7,077 	7,073
Prepaid expenses and other current assets 	2,428 	1,858
TOTAL CURRENT ASSETS 	22,458 	22,648
PROPERTY, PLANT AND EQUIPMENT, NET 	22,027 	21,909
GOODWILL 	40,567 	40,659
TRADEMARKS AND OTHER INTANGIBLE ASSETS, NET 	22,193 	23,783
OTHER NONCURRENT ASSETS 	12,353 	11,830
TOTAL ASSETS 	$ 	119,598 $ 	120,829
Liabilities and Shareholders' Equity
CURRENT LIABILITIES
Accounts payable 	$ 	13,691 $ 	14,598
Accrued and other liabilities 	10,921 	10,929
Debt due within one year 	7,729 	10,229
TOTAL CURRENT LIABILITIES 	32,340 	35,756
LONG-TERM DEBT 	24,253 	24,378
DEFERRED INCOME TAXES 	6,284 	6,478
OTHER NONCURRENT LIABILITIES 	6,386 	7,152
TOTAL LIABILITIES 	69,264 	73,764
SHAREHOLDERS’ EQUITY
Preferred stock 	801 	819
Common stock – shares issued – 	March 2024 	4,009.2
June 2023 	4,009.2 	4,009 	4,009
Additional paid-in capital 	67,395 	66,556
Reserve for ESOP debt retirement 	(737) 	(821)
Accumulated other comprehensive loss 	(12,370) 	(12,220)
Treasury stock 	(132,172) 	(129,736)
Retained earnings 	123,132 	118,170
Noncontrolling interest 	275 	288
TOTAL SHAREHOLDERS’ EQUITY 	50,333 	47,065
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY 	$ 	119,598 $ 	120,829
See accompanying Notes to Consolidated Financial Statements.

-- 4 of 39 --

The Procter & Gamble Company 3
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
Three Months Ended March 31, 2024
Dollars in millions;
shares in thousands
Common Stock 	Preferred
Stock
Additional
Paid-In
Capital
Reserve for
ESOP Debt
Retirement
Accumulated
Other
Comprehensive
Income/(Loss) Treasury Stock Retained
Earnings Noncontrolling
Interest
Total
Shareholders'
Equity	Shares 	Amount
BALANCE DECEMBER 31,
2023 	2,353,021 $4,009 	$809 	$66,935 	($782) 	($12,167) ($131,887) 	$121,617 	$294 	$48,829
Net earnings 	3,754 	27 	3,781
Other comprehensive
income/(loss) 	(203) 	(1) 	(204)
Dividends and dividend
equivalents
($0.9407 per share):
Common 	(2,221) 	(2,221)
Preferred 	(69) 	(69)
Treasury stock purchases 	(6,046) 	(977) 	(977)
Employee stock plans 	12,201 	459 	685 	1,144
Preferred stock conversions 	959 	(8) 	1 	7 	—
ESOP debt impacts 	45 	51 	97
Noncontrolling interest, net 	— 	(46) 	(46)
BALANCE MARCH 31, 2024 	2,360,135 $4,009 	$801 	$67,395 	($737) 	($12,370) ($132,172) 	$123,132 	$275 	$50,333
Nine Months Ended March 31, 2024
Dollars in millions;
shares in thousands
Common Stock 	Preferred
Stock
Additional
Paid-In
Capital
Reserve for
ESOP Debt
Retirement
Accumulated
Other
Comprehensive
Income/(Loss) Treasury Stock
Retained
Earnings
Noncontrolling
Interest
Total
Shareholders'
Equity	Shares 	Amount
BALANCE JUNE 30, 2023 	2,362,120 $4,009 	$819 	$66,556 	($821) 	($12,220) ($129,736) 	$118,170 	$288 	$47,065
Net earnings 	11,742 	88 	11,830
Other comprehensive
income/(loss) 	(150) 	(3) 	(153)
Dividends and dividend
equivalents
($2.8221 per share):
Common 	(6,671) 	(6,671)
Preferred 	(209) 	(209)
Treasury stock purchases 	(22,768) 	(3,493) 	(3,493)
Employee stock plans 	18,552 	836 	1,041 	1,878
Preferred stock conversions 	2,232 	(18) 	3 	15 	—
ESOP debt impacts 	85 	99 	184
Noncontrolling interest, net 	— 	(98) 	(98)
BALANCE MARCH 31, 2024 	2,360,135 $4,009 	$801 	$67,395 	($737) 	($12,370) ($132,172) 	$123,132 	$275 	$50,333
See accompanying Notes to Consolidated Financial Statements.

-- 5 of 39 --

4 The Procter & Gamble Company
Three Months Ended March 31, 2023
Dollars in millions;
shares in thousands
Common Stock 	Preferred
Stock
Additional
Paid-In
Capital
Reserve for
ESOP Debt
Retirement
Accumulated
Other
Comprehensive
Income/(Loss) Treasury Stock Retained
Earnings Noncontrolling
Interest
Total
Shareholders'
Equity	Shares 	Amount
BALANCE DECEMBER 31,
2022 	2,359,144 $4,009 	$831 	$66,145 	($870) 	($12,506) ($129,012) 	$115,858 	$270 	$44,725
Net earnings 	3,397 	27 	3,424
Other comprehensive
income/(loss) 	240 	1 	241
Dividends and dividend
equivalents
($0.9133 per share):
Common 	(2,160) 	(2,160)
Preferred 	(69) 	(69)
Treasury stock purchases 	(9,406) 	(1,351) 	(1,351)
Employee stock plans 	6,290 	170 	353 	523
Preferred stock conversions 	941 	(9) 	1 	8 	—
ESOP debt impacts 	49 	56 	105
Noncontrolling interest, net 	— 	(17) 	(17)
BALANCE MARCH 31, 2023 	2,356,969 $4,009 	$822 	$66,316 	($821) 	($12,266) ($130,002) 	$117,082 	$281 	$45,421
Nine Months Ended March 31, 2023
Dollars in millions;
shares in thousands
Common Stock 	Preferred
Stock
Additional
Paid-In
Capital
Reserve for
ESOP Debt
Retirement
Accumulated
Other
Comprehensive
Income/(Loss) Treasury Stock Retained
Earnings Noncontrolling
Interest
Total
Shareholders'
Equity	Shares 	Amount
BALANCE JUNE 30, 2022 	2,393,877 $4,009 	$843 	$65,795 	($916) 	($12,189) ($123,382) 	$112,429 	$265 	$46,854
Net earnings 	11,269 	77 	11,346
Other comprehensive
income/(loss) 	(77) 	(7) 	(84)
Dividends and dividend
equivalents
($2.7399 per share):
Common 	(6,517) 	(6,517)
Preferred 	(210) 	(210)
Treasury stock purchases 	(52,021) 	(7,353) 	(7,353)
Employee stock plans 	12,742 	518 	715 	1,233
Preferred stock conversions 	2,371 	(21) 	3 	18 	—
ESOP debt impacts 	95 	111 	206
Noncontrolling interest, net 	— 	(54) 	(54)
BALANCE MARCH 31, 2023 	2,356,969 $4,009 	$822 	$66,316 	($821) 	($12,266) ($130,002) 	$117,082 	$281 	$45,421
See accompanying Notes to Consolidated Financial Statements.

-- 6 of 39 --

The Procter & Gamble Company 5
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
Nine Months Ended March 31
Amounts in millions 	2024 	2023
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING OF PERIOD 	$ 	8,246 $ 	7,214
OPERATING ACTIVITIES
Net earnings 	11,830 	11,346
Depreciation and amortization 	2,135 	2,008
Share-based compensation expense 	433 	406
Deferred income taxes 	(206) 	(360)
Gain on sale of assets 	(51) 	(4)
Indefinite-lived intangible asset impairment charge 	1,341 	—
Changes in:
Accounts receivable 	(692) 	(301)
Inventories 	(47) 	(503)
Accounts payable and accrued and other liabilities 	56 	(609)
Other operating assets and liabilities 	(1,196) 	(839)
Other 	490 	363
TOTAL OPERATING ACTIVITIES 	14,092 	11,507
INVESTING ACTIVITIES
Capital expenditures 	(2,539) 	(2,328)
Proceeds from asset sales 	77 	9
Acquisitions, net of cash acquired 	(21) 	(714)
Other investing activity 	(503) 	331
TOTAL INVESTING ACTIVITIES 	(2,986) 	(2,702)
FINANCING ACTIVITIES
Dividends to shareholders 	(6,863) 	(6,710)
Additions to short-term debt with original maturities of more than three months 	2,961 	13,778
Reductions in short-term debt with original maturities of more than three months 	(7,523) 	(9,134)
Net additions/(reductions) to other short-term debt 	2,331 	(387)
Additions to long-term debt 	1,598 	2,569
Reductions in long-term debt 	(2,335) 	(1,877)
Treasury stock purchases 	(3,490) 	(7,353)
Impact of stock options and other 	965 	861
TOTAL FINANCING ACTIVITIES 	(12,356) 	(8,253)
EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS AND RESTRICTED CASH 	(168) 	(170)
CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH 	(1,418) 	382
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, END OF PERIOD 	$ 	6,828 $ 	7,596
See accompanying Notes to Consolidated Financial Statements.

-- 7 of 39 --

6 The Procter & Gamble Company
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Basis of Presentation
The accompanying unaudited Consolidated Financial Statements of The Procter & Gamble Company and subsidiaries ("the Company," "Procter & Gamble,"
"P&G," "we" or "our") should be read in conjunction with the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2023. We have
prepared these statements in conformity with accounting principles generally accepted in the United States (U.S. GAAP) pursuant to the rules and regulations
of the U.S. Securities and Exchange Commission (SEC) for interim financial information. Note that certain columns and rows may not add due to rounding. In
the opinion of management, the accompanying Consolidated Financial Statements contain all normal recurring adjustments necessary to present fairly the
financial position, results of operations and cash flows for the interim periods reported. However, the results of operations included in such financial statements
may not necessarily be indicative of annual results.
2. New Accounting Pronouncements and Policies
In November 2023, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2023-07, “Segment Reporting:
Improvements to Reportable Segment Disclosures.” This guidance requires disclosure of incremental segment information on an annual and interim basis. This
amendment is effective for our fiscal year ending June 30, 2025 and our interim periods within the fiscal year ending June 30, 2026. We are currently assessing
the impact of this guidance on our disclosures.
In December 2023, the FASB issued ASU No. 2023-09, “Income Taxes: Improvements to Income Tax Disclosures.” This guidance requires consistent
categories and greater disaggregation of information in the rate reconciliation and disclosures of income taxes paid by jurisdiction. This amendment is effective
for our fiscal year ending June 30, 2026. We are currently assessing the impact of this guidance on our disclosures.
No other new accounting pronouncement issued or effective during the fiscal year had, or is expected to have, a material impact on our Consolidated Financial
Statements.
3. Segment Information
Under U.S. GAAP, our operating segments are aggregated into five reportable segments: 1) Beauty, 2) Grooming, 3) Health Care, 4) Fabric & Home Care and
5) Baby, Feminine & Family Care. Our five reportable segments are comprised of:
• Beauty: Hair Care (Conditioners, Shampoos, Styling Aids, Treatments); Skin and Personal Care (Antiperspirants and Deodorants, Personal Cleansing, Skin
Care);
• Grooming: Grooming (Appliances, Female Blades & Razors, Male Blades & Razors, Pre- and Post-Shave Products, Other Grooming);
• Health Care: Oral Care (Toothbrushes, Toothpaste, Other Oral Care); Personal Health Care (Gastrointestinal, Pain Relief, Rapid Diagnostics, Respiratory,
Vitamins/Minerals/Supplements, Other Personal Health Care);
• Fabric & Home Care: Fabric Care (Fabric Enhancers, Laundry Additives, Laundry Detergents); Home Care (Air Care, Dish Care, P&G Professional,
Surface Care); and
• Baby, Feminine & Family Care: Baby Care (Baby Wipes, Taped Diapers and Pants); Feminine Care (Adult Incontinence, Feminine Care); Family Care
(Paper Towels, Tissues, Toilet Paper).
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 8 of 39 --

The Procter & Gamble Company 7
Our operating segments are comprised of similar product categories. Operating segments that individually accounted for 5% or more of consolidated net sales
are as follows:
% of Net sales by operating segment
Three Months Ended March 31 	Nine Months Ended March 31
2024 	2023 	2024 	2023
Fabric Care 	23 % 	23 % 	23 % 	23 %
Home Care 	13 % 	12 % 	12 % 	12 %
Baby Care 	9 % 	10 % 	9 % 	10 %
Family Care 	9 % 	9 % 	9 % 	8 %
Hair Care 	9 % 	9 % 	9 % 	9 %
Skin and Personal Care 	9 % 	9 % 	9 % 	10 %
Grooming 	8 % 	8 % 	8 % 	8 %
Oral Care 	8 % 	8 % 	8 % 	8 %
Personal Health Care 	6 % 	6 % 	7 % 	6 %
Feminine Care 	6 % 	6 % 	6 % 	6 %
Total 	100 % 	100 % 	100 % 	100 %
% of Net sales by operating segment excludes sales recorded in Corporate.
The following is a summary of reportable segment results:
Three Months Ended March 31 	Nine Months Ended March 31
Net Sales
Earnings/(Loss)
Before Income
Taxes
Net
Earnings/(Loss) 	Net Sales
Earnings/(Loss)
Before Income
Taxes
Net
Earnings/(Loss)
Beauty 	2024 $ 	3,550 $ 	753 $ 	587 $ 	11,496 $ 	3,114 $ 	2,426
2023 	3,494 	763 	608 	11,262 	3,179 	2,530
Grooming 	2024 	1,539 	379 	303 	4,997 	1,450 	1,165
2023 	1,495 	382 	308 	4,763 	1,381 	1,116
Health Care 	2024 	2,873 	687 	525 	9,119 	2,508 	1,933
2023 	2,828 	667 	523 	8,636 	2,354 	1,826
Fabric & Home Care 	2024 	7,169 	1,692 	1,301 	22,230 	5,741 	4,446
2023 	7,016 	1,538 	1,174 	21,130 	4,619 	3,517
Baby, Feminine & Family Care 	2024 	4,936 	1,299 	997 	15,268 	4,144 	3,174
2023 	5,062 	1,206 	925 	15,061 	3,373 	2,578
Corporate 	2024 	128 	(218) 	68 	398 	(2,066) 	(1,314)
2023 	173 	(268) 	(114) 	601 	(786) 	(221)
Total Company 	2024 $ 	20,195 $ 	4,592 $ 	3,781 $ 	63,507 $ 	14,891 $ 	11,830
2023 	20,068 	4,288 	3,424 	61,453 	14,120 	11,346
4. Goodwill and Intangible Assets
Goodwill is allocated by reportable segment as follows:
Beauty 	Grooming 	Health Care
Fabric & Home
Care
Baby, Feminine &
Family Care 	Total Company
Goodwill at June 30, 2023 	$ 	13,888 $ 	12,703 $ 	7,718 $ 	1,821 $ 	4,529 $ 	40,659
Acquisitions and divestitures 	— 	— 	— 	— 	— 	—
Translation and other 	(32) 	(19) 	(24) 	(6) 	(11) 	(92)
Goodwill at March 31, 2024 	$ 	13,856 $ 	12,685 $ 	7,695 $ 	1,815 $ 	4,518 $ 	40,567
Goodwill decreased from June 30, 2023, due to currency translation.
(1)
(1)
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 9 of 39 --

8 The Procter & Gamble Company
Identifiable intangible assets at March 31, 2024, were comprised of:
Gross Carrying Amount 	Accumulated Amortization
Intangible assets with determinable lives 	$ 	9,046 	$ 	(6,499)
Intangible assets with indefinite lives 	19,645 	—
Total identifiable intangible assets 	$ 	28,691 	$ 	(6,499)
Intangible assets with determinable lives consist of brands, patents, technology and customer relationships. The intangible assets with indefinite lives primarily
consist of brands. The amortization expense of determinable-lived intangible assets for the three months ended March 31, 2024 and 2023, was $83 and $82,
respectively. For the nine months ended March 31, 2024 and 2023, amortization expense was $255 and $241, respectively.
Goodwill and indefinite-lived intangible assets are not amortized but are tested at least annually for impairment. We use the income method to estimate the fair
value of these assets, which is based on forecasts of the expected future cash flows attributable to the respective assets. When appropriate, the market approach,
which leverages comparable company revenue and earnings multiples, is weighted with the income approach to estimate fair value. If the resulting fair value is
less than the asset's carrying value, that difference represents an impairment. Our annual impairment testing for goodwill and indefinite-lived intangible assets
occurs during the three months ended December 31. Most of our goodwill reporting units have fair value cushions that significantly exceed their underlying
carrying values.
During the three months ended December 31, 2023, we determined that the fair value of the Gillette indefinite-lived intangible asset was less than its carrying
amount. As a result, we recorded a non-cash impairment charge of $1.3 billion ($1.0 billion after tax) to reduce the carrying amount to be equivalent to the
estimated fair value as of December 31, 2023. Following the impairment charge, the carrying value of the Gillette indefinite-lived intangible asset is $12.8
billion. The impairment charge arose due to a higher discount rate, weakening of several currencies relative to the U.S. dollar and the impact of a new
restructuring program focused primarily in certain Enterprise Markets, including Argentina and Nigeria.
While we have concluded that no triggering event has occurred during the quarter ended March 31, 2024, the Gillette indefinite-lived intangible asset is
susceptible to further impairment risk. Adverse changes in the business or in the macroeconomic environment, including foreign currency devaluation,
increasing global inflation, market contraction from an economic recession and the Russia-Ukraine War, could reduce the underlying cash flows used to
estimate the fair value of the Gillette indefinite-lived intangible asset and trigger a further impairment charge. Further reduction of the Gillette business
activities in Russia could reduce the estimated fair value. The Russia business accounted for approximately 4% of Gillette net sales in the fiscal year ended
June 30, 2023.
The most significant assumptions utilized in the determination of the estimated fair value of the Gillette indefinite-lived intangible asset are the net sales
growth rates (including residual growth rates), discount rate and royalty rates.
Net sales growth rates could be negatively impacted by reductions or changes in demand for our Gillette products, which may be caused by, among other
things: changes in the use and frequency of grooming products, shifts in demand away from one or more of our higher priced products to lower priced products
or potential supply chain constraints. In addition, relative global and country/regional macroeconomic factors, including the Russia-Ukraine War, could result
in additional and prolonged devaluation of other countries' currencies relative to the U.S. dollar. The residual growth rates represent the expected rate at which
the Gillette brand is expected to grow beyond the shorter-term business planning period. The residual growth rates utilized in our fair value estimates are
consistent with the brand operating plans and approximate expected long-term category market growth rates. The residual growth rate depends on overall
market growth rates, the competitive environment, inflation, relative currency exchange rates and business activities that impact market share. As a result, the
residual growth rate could be adversely impacted by a sustained deceleration in category growth, grooming habit changes, devaluation of currencies against the
U.S. dollar or an increased competitive environment.
The discount rate, which is consistent with a weighted average cost of capital that is likely to be expected by a market participant, is based upon industry
required rates of return, including consideration of both debt and equity components of the capital structure. Our discount rate may be impacted by adverse
changes in the macroeconomic environment, volatility in the equity and debt markets or other country specific factors, such as further devaluation of currencies
against the U.S. dollar. Spot rates as of the fair value measurement date are utilized in our fair value estimates for cash flows outside the U.S.
The royalty rate used to determine the estimated fair value for the Gillette indefinite-lived intangible asset is driven by historical and estimated future
profitability of the underlying Gillette business. The royalty rate may be impacted by significant adverse changes in long-term operating margins.
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 10 of 39 --

The Procter & Gamble Company 9
We performed a sensitivity analysis for the Gillette indefinite-lived intangible asset as part of our annual impairment testing during the three months ended
December 31, 2023, utilizing reasonably possible changes in the assumptions for the discount rate, the short-term and residual growth rates and the royalty rate
to demonstrate the potential impacts to estimated fair values. The table below provides, in isolation, the estimated fair value impacts related to a 25 basis-point
increase in the discount rate, a 25 basis-point decrease in our short-term and residual growth rates or a 50 basis-point decrease in our royalty rate, which may
result in an additional impairment of the Gillette indefinite-lived intangible asset.
Approximate Percent Change in Estimated Fair Value
+25 bps Discount Rate 	-25 bps Growth Rates 	-50 bps Royalty Rate
Gillette indefinite-lived intangible asset 	(5)% 	(5)% 	(4)%
5. Earnings Per Share
Basic net earnings per common share are calculated by dividing Net earnings attributable to Procter & Gamble less preferred dividends by the weighted
average number of common shares outstanding during the period. Diluted net earnings per common share are calculated by dividing Net earnings attributable
to Procter & Gamble by the diluted weighted average number of common shares outstanding during the period. The diluted shares include the dilutive effect of
stock options and other share-based awards based on the treasury stock method and the assumed conversion of preferred stock.
Net earnings per common share were calculated as follows:
CONSOLIDATED AMOUNTS 	Three Months Ended March 31 Nine Months Ended March 31
2024 	2023 	2024 	2023
Net earnings 	$ 	3,781 $ 	3,424 $ 	11,830 $ 	11,346
Less: Net earnings attributable to noncontrolling interests 	27 	27 	88 	77
Net earnings attributable to P&G (Diluted) 	3,754 	3,397 	11,742 	11,269
Less: Preferred dividends 	69 	69 	209 	210
Net earnings attributable to P&G available to common shareholders (Basic) 	$ 	3,685 $ 	3,328 $ 	11,533 $ 	11,059
SHARES IN MILLIONS
Basic weighted average common shares outstanding 	2,360.5 	2,359.1 	2,359.5 	2,370.2
Add: Effect of dilutive securities
Convertible preferred shares 	73.3 	76.0 	73.9 	76.7
Stock options and other unvested equity awards 	38.1 	38.1 	38.4 	39.1
Diluted weighted average common shares outstanding 	2,472.0 	2,473.2 	2,471.8 	2,486.0
NET EARNINGS PER COMMON SHARE
Basic 	$ 	1.56 $ 	1.41 $ 	4.89 $ 	4.67
Diluted 	$ 	1.52 $ 	1.37 $ 	4.75 $ 	4.53
An overview of preferred shares can be found in our Annual Report on Form 10-K for the fiscal year ended June 30, 2023.
Excludes approximately 6 million and 21 million for the three months ended March 31, 2024 and 2023, respectively, and 6 million and 20 million for the nine months ended
March 31, 2024 and 2023, respectively, of weighted average stock options outstanding because the exercise price of these options was greater than their average market
value or their effect was antidilutive.
6. Share-Based Compensation and Postretirement Benefits
The following table provides a summary of our share-based compensation expense and postretirement benefit impacts:
Three Months Ended March 31 Nine Months Ended March 31
2024 	2023 	2024 	2023
Share-based compensation expense 	$ 	158 $ 	156 $ 	433 $ 	406
Net periodic benefit cost for pension benefits 	52 	45 	160 	132
Net periodic benefit credit for other retiree benefits 	(156) 	(131) 	(467) 	(395)
(1)
(2)
(1)
(2)
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 11 of 39 --

10 The Procter & Gamble Company
7. Risk Management Activities and Fair Value Measurements
As a multinational company with diverse product offerings, we are exposed to market risks, such as changes in interest rates, currency exchange rates and
commodity prices. There have been no significant changes in our risk management policies or activities during the nine months ended March 31, 2024.
The Company has not changed its valuation techniques used in measuring the fair value of any financial assets and liabilities during the period. The Company
recognizes transfers between levels within the fair value hierarchy, if any, at the end of each quarter. There were no transfers between levels during the periods
presented. Also, there was no significant activity within the Level 3 assets and liabilities during the periods presented. Except for the impairment of the Gillette
indefinite-lived intangible asset discussed in Note 4, there were no significant assets or liabilities that were re-measured at fair value on a non-recurring basis
during the nine months ended March 31, 2024 and 2023.
Cash equivalents were $5.4 billion and $6.8 billion as of March 31, 2024 and June 30, 2023, respectively, and are classified as Level 1 within the fair value
hierarchy. The Company had no other material investments in debt or equity securities during the periods presented.
The fair value of long-term debt was $26.4 billion and $26.9 billion as of March 31, 2024 and June 30, 2023, respectively. This includes the current portion of
long-term debt instruments ($3.4 billion and $3.9 billion as of March 31, 2024 and June 30, 2023, respectively). Certain long-term debt (debt designated as a
fair value hedge) is recorded at fair value. All other long-term debt is recorded at amortized cost but is measured at fair value for disclosure purposes. We
consider our debt to be Level 2 in the fair value hierarchy. Fair values are generally estimated based on quoted market prices for identical or similar
instruments.
Disclosures about Financial Instruments
The notional amounts and fair values of financial instruments used in hedging transactions as of March 31, 2024 and June 30, 2023, are as follows:
Notional Amount 	Fair Value Asset 	Fair Value (Liability)
March 31, 2024 	June 30, 2023 	March 31, 2024 	June 30, 2023 	March 31, 2024 	June 30, 2023
DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS
Interest rate contracts 	$ 	3,030 $ 	4,044 $ 	— $ 	— $ 	(323) $ 	(445)
DERIVATIVES IN NET INVESTMENT HEDGING RELATIONSHIPS
Foreign currency interest rate contracts 	$ 	10,926 $ 	11,005 $ 	79 $ 	26 $ 	(108) $ 	(631)
TOTAL DERIVATIVES DESIGNATED AS
HEDGING INSTRUMENTS 	$ 	13,956 $ 	15,049 $ 	79 $ 	26 $ 	(432) $ 	(1,076)
DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS
Foreign currency contracts 	$ 	3,956 $ 	3,489 $ 	12 $ 	7 $ 	(23) $ 	(42)
TOTAL DERIVATIVES AT FAIR VALUE 	$ 	17,912 $ 	18,538 $ 	91 $ 	33 $ 	(455) $ 	(1,118)
The fair value of the interest rate derivative asset/(liability) directly offsets the cumulative amount of the fair value hedging adjustment included in the carrying
amount of the underlying debt obligation. The carrying amount of the underlying debt obligation, which includes the unamortized discount or premium and the
fair value adjustment, was $2.7 billion and $3.6 billion as of March 31, 2024 and June 30, 2023, respectively. In addition to the foreign currency derivative
contracts designated as net investment hedges, certain of our foreign currency denominated debt instruments are designated as net investment hedges. The
carrying value of those debt instruments designated as net investment hedges, which includes the adjustment for the foreign currency transaction gain or loss on
those instruments, was $10.5 billion and $11.8 billion as of March 31, 2024 and June 30, 2023, respectively.
Derivative assets are presented in Prepaid expenses and other current assets or Other noncurrent assets. Derivative liabilities are presented in Accrued and other
liabilities or Other noncurrent liabilities. Changes in the fair value of net investment hedges are recognized in the Foreign currency translation component of
Other comprehensive income (OCI). All of the Company's derivative assets and liabilities measured at fair value are classified as Level 2 within the fair value
hierarchy.
Certain of the Company's financial instruments used in hedging transactions are governed by industry standard netting and collateral agreements with
counterparties. If the Company's credit rating were to fall below the levels stipulated in the agreements, the counterparties could demand either collateralization
or termination of the arrangements. The aggregate fair value of the instruments covered by these contractual features that are in a net liability position was $363
and $1,088 as of March 31, 2024 and June 30, 2023, respectively. The Company has not been required to post collateral as a result of these contractual features.
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 12 of 39 --

The Procter & Gamble Company 11
Before tax gains on our financial instruments in hedging relationships are categorized as follows:
Amount of Gain/(Loss) Recognized in OCI on Derivatives
Three Months Ended March 31 	Nine Months Ended March 31
2024 	2023 	2024 	2023
DERIVATIVES IN NET INVESTMENT HEDGING RELATIONSHIPS
Foreign exchange contracts 	$ 	269 $ 	(266) $ 	67 $ 	(571)
For the derivatives in net investment hedging relationships, the amount of gain excluded from effectiveness testing, which was recognized in earnings, was $53 and $64 for
the three months ended March 31, 2024 and 2023, respectively. The amount of gain excluded from effectiveness testing was $182 and $179 for the nine months ended
March 31, 2024 and 2023, respectively.
In addition to the foreign currency derivative contracts designated as net investment hedges, certain of our foreign currency denominated debt instruments are designated as
net investment hedges. The amount of gain/(loss) recognized in Accumulated other comprehensive income (AOCI) for such instruments was $262 and $(242) for the three
months ended March 31, 2024 and 2023, respectively. The amount of gain/(loss) recognized in Accumulated other comprehensive income (AOCI) for such instruments was
$102 and $(406) for the nine months ended March 31, 2024 and 2023, respectively.
Amount of Gain/(Loss) Recognized in Earnings
Three Months Ended March 31 	Nine Months Ended March 31
2024 	2023 	2024 	2023
DERIVATIVES IN FAIR VALUE HEDGING RELATIONSHIPS
Interest rate contracts 	$ 	(7) $ 	39 $ 	122 $ 	(141)
DERIVATIVES NOT DESIGNATED AS HEDGING INSTRUMENTS
Foreign currency contracts 	$ 	(84) $ 	38 $ 	(27) $ 	(13)
The gains/(losses) on the derivatives in fair value hedging relationships are fully offset by the mark-to-market impact of the related exposure. These are both
recognized in Interest expense. The gains/(losses) on derivatives not designated as hedging instruments are substantially offset by the currency mark-to-market
of the related exposure. These are both recognized in Selling, general and administrative expense (SG&A).
8. Accumulated Other Comprehensive Income/(Loss)
The table below presents the changes in Accumulated other comprehensive income/(loss) attributable to Procter & Gamble (AOCI), including the
reclassifications out of AOCI by component:
Investment
Securities
Postretirement
Benefit Plans
Foreign Currency
Translation 	Total AOCI
Balance at June 30, 2023 	$ 	13 $ 	67 $ 	(12,300) $ 	(12,220)
OCI before reclassifications 	(2) 	(3) 	(128) 	(133)
Amounts reclassified to the Consolidated Statement of Earnings 	(19) 	(19)
Net current period OCI 	(2) 	(23) 	(128) 	(153)
Less: OCI attributable to noncontrolling interests 	— 	(3) 	(3)
Balance at March 31, 2024 	$ 	11 $ 	44 $ 	(12,425) $ 	(12,370)
Net of tax (benefit)/expense of $0, $(3) and $40 for gains/losses on investment securities, postretirement benefit plans and foreign currency translation, respectively. Income
tax effects within foreign currency translation include impacts from items such as net investment hedge transactions.
Net of tax (benefit)/expense of $0, $(3) and $0 for gains/losses on investment securities, postretirement benefit plans and foreign currency translation, respectively.
Postretirement benefit plan amounts are reclassified from AOCI into Other non-operating income, net and included in the computation of net periodic
postretirement costs.
9. Commitments and Contingencies
Litigation
We are subject, from time to time, to certain legal proceedings and claims arising out of our business, which cover a wide range of matters, including antitrust
and trade regulation, product liability, advertising, contracts, environmental, patent and trademark matters, labor and employment matters and tax. While
considerable uncertainty exists, in the opinion of management and our counsel, the ultimate resolution of the various lawsuits and claims will not materially
affect our financial position, results of operations or cash flows.
(1) (2)
(1)
(2)
(1)
(2)
(1)
(2)
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 13 of 39 --

12 The Procter & Gamble Company
We are also subject to contingencies pursuant to environmental laws and regulations that in the future may require us to take action to correct the effects on the
environment of prior manufacturing and waste disposal practices. Based on currently available information, we do not believe the ultimate resolution of
environmental remediation will materially affect our financial position, results of operations or cash flows.
Income Tax Uncertainties
The Company is present in approximately 70 countries and over 150 taxable jurisdictions and, at any point in time, has 30–40 jurisdictional audits underway at
various stages of completion. We evaluate our tax positions and establish liabilities for uncertain tax positions that may be challenged by local authorities and
may not be fully sustained, despite our belief that the underlying tax positions are fully supportable. Uncertain tax positions are reviewed on an ongoing basis
and are adjusted in light of changing facts and circumstances, including progress of tax audits, developments in case law and closing of statutes of limitations.
Such adjustments are reflected in the tax provision as appropriate. We have tax years open ranging from 2010 and forward. We are generally not able to reliably
estimate the timing and ultimate settlement amounts until the close of an audit. Based on information currently available, we anticipate that over the next 12-
month period, audit activity could be completed related to uncertain tax positions in multiple jurisdictions for which we have accrued existing liabilities of
approximately $90, including interest and penalties.
Additional information on the Commitments and Contingencies of the Company can be found in our Annual Report on Form 10-K for the fiscal year ended
June 30, 2023.
10. Supplier Finance Programs
The Company has an ongoing program to negotiate extended payment terms with its suppliers consistent with market practices. The Company also supports a
Supply Chain Finance program (“SCF”) with several global financial institutions. Under SCF, the Company maintains an accounts payable system to facilitate
participating suppliers' ability to sell receivables from the Company to a SCF bank. These participating suppliers negotiate their sales of receivables
arrangements directly with the respective SCF bank. The Company is not party to those agreements, but the SCF banks allow the suppliers to utilize the
Company’s creditworthiness in establishing credit spreads and associated costs. Under this model, this arrangement generally provides the suppliers with more
favorable terms than they would be able to secure on their own. The Company has no economic interest in a supplier’s decision to sell a receivable. Once a
qualifying supplier chooses to participate in SCF, the supplier selects which individual Company invoices to sell to the SCF bank. The Company’s obligations
to its suppliers, including the amounts due and scheduled payment dates, are not impacted by the supplier’s decisions to finance amounts under these
arrangements. The Company does not provide any form of guarantee under these financing arrangements. Our payment terms for suppliers under this program
generally range from 60 to 180 days. All outstanding amounts related to suppliers participating in SCF are recorded within Accounts payable in our
Consolidated Balance Sheets, and the associated payments are included in operating activities within our Consolidated Statements of Cash Flows. The amount
due to suppliers participating in SCF and included in Accounts payable was approximately $5.2 billion as of March 31, 2024, $5.7 billion as of June 30, 2023,
and $5.8 billion as of June 30, 2022.
11. Restructuring Program
The Company has historically incurred an ongoing annual level of restructuring-type activities to maintain a competitive cost structure, including
manufacturing and workforce optimization. Before tax costs incurred under the ongoing program have generally ranged from $250 to $500 annually.
Consistent with our historical policies for restructuring-type activities, the restructuring program charges will be funded by and included within Corporate for
management and segment reporting.
In December 2023, the Company announced a limited market portfolio restructuring of its business operations, primarily in certain Enterprise Markets,
including Argentina and Nigeria, to address challenging macroeconomic and fiscal conditions. In connection with this announcement, the Company expects to
record incremental restructuring charges of $1.0 to $1.5 billion after tax, consisting primarily of foreign currency translation losses to be recognized as non-
cash charges upon the substantial liquidation of operations in the affected markets.
For the three months ended March 31, 2024, the Company incurred charges of $70 including $44 in Costs of products sold, $25 in SG&A and $1 in Other non-
operating income. For the nine months ended March 31, 2024, the Company incurred charges of $252 including $154 in Costs of products sold, $93 in SG&A
and $5 in Other non-operating income.
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 14 of 39 --

The Procter & Gamble Company 13
The following table presents restructuring activity for the nine months ended March 31, 2024:
Separation Costs 	Asset-Related Costs 	Other Costs 	Total
RESERVE JUNE 30, 2023 	$ 	155 $ 	— $ 	19 $ 	174
Costs incurred for the six months ended December 31, 2023 	109 	42 	30 	181
Costs incurred for the three months ended March 31, 2024 	37 	11 	22 	70
Costs incurred for the nine months ended March 31, 2024 	146 	52 	53 	252
Costs paid/settled for the nine months ended March 31, 2024 	(190) 	(52) 	(52) 	(294)
RESERVE MARCH 31, 2024 	$ 	112 $ 	— $ 	19 $ 	131
Separation Costs
Employee separation costs relate to severance packages that are primarily voluntary and the amounts calculated are based on salary levels and past service
periods.
Asset-Related Costs
Asset-related costs consist of both asset write-downs and accelerated depreciation for manufacturing consolidations. Asset write-downs relate to the
establishment of a new fair value basis for assets held-for-sale or for disposal. These assets are written down to the lower of their current carrying basis or
amounts expected to be realized upon disposal, less minor disposal costs. Charges for accelerated depreciation relate to long-lived assets that will be taken out
of service prior to the end of their normal service period.
Other Costs
Other restructuring-type charges are incurred as a direct result of the restructuring plan. Such charges include asset removal and termination of contracts related
to supply chain and overhead optimization.
Item 2. 	Management's Discussion and Analysis of Financial Condition and Results of Operations
Forward-Looking Statements
Certain statements in this report, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives
and expected operating results, and the assumptions upon which those statements are based, are “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-
looking statements may appear throughout this report, including without limitation, the following sections: “Management's Discussion and Analysis,” “Risk
Factors” and "Notes 4 and 9 to the Consolidated Financial Statements." These forward-looking statements generally are identified by the words “believe,”
“project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,”
“will likely result” and similar expressions. Forward-looking statements are based on current expectations and assumptions, which are subject to risks and
uncertainties that may cause results to differ materially from those expressed or implied in the forward-looking statements. We undertake no obligation to
update or revise publicly any forward-looking statements, whether because of new information, future events or otherwise, except to the extent required by law.
Risks and uncertainties to which our forward-looking statements are subject include, without limitation: (1) the ability to successfully manage global financial
risks, including foreign currency fluctuations, currency exchange or pricing controls and localized volatility; (2) the ability to successfully manage local,
regional or global economic volatility, including reduced market growth rates, and to generate sufficient income and cash flow to allow the Company to effect
the expected share repurchases and dividend payments; (3) the ability to manage disruptions in credit markets or to our banking partners or changes to our
credit rating; (4) the ability to maintain key manufacturing and supply arrangements (including execution of supply chain optimizations and sole supplier and
sole manufacturing plant arrangements) and to manage disruption of business due to various factors, including ones outside of our control, such as natural
disasters, acts of war (including the Russia-Ukraine War) or terrorism or disease outbreaks; (5) the ability to successfully manage cost fluctuations and
pressures, including prices of commodities and raw materials and costs of labor, transportation, energy, pension and healthcare; (6) the ability to stay on the
leading edge of innovation, obtain necessary intellectual property protections and successfully respond to changing consumer habits, evolving digital marketing
and selling platform requirements and technological advances attained by, and patents granted to, competitors; (7) the ability to compete with our local and
global competitors in new and existing sales channels, including by successfully responding to competitive factors such as prices, promotional incentives and
trade terms for products; (8) the ability to manage and maintain key customer relationships; (9) the ability to protect our reputation and brand equity by
successfully managing real or perceived issues, including concerns about safety, quality, ingredients, efficacy, packaging content, supply chain practices or
similar matters that may arise; (10) the ability to successfully manage the financial, legal, reputational and operational risk associated with third-party
relationships, such as our suppliers, contract manufacturers,
Amounts in millions of dollars except per share amounts or as otherwise specified.

-- 15 of 39 --

14 The Procter & Gamble Company
distributors, contractors and external business partners; (11) the ability to rely on and maintain key company and third-party information and operational
technology systems, networks and services and maintain the security and functionality of such systems, networks and services and the data contained therein;
(12) the ability to successfully manage uncertainties related to changing political and geopolitical conditions and potential implications such as exchange rate
fluctuations and market contraction; (13) the ability to successfully manage current and expanding regulatory and legal requirements and matters (including,
without limitation, those laws and regulations involving product liability, product and packaging composition, intellectual property, labor and employment,
antitrust, privacy and data protection, tax, the environment, due diligence, risk oversight, accounting and financial reporting) and to resolve new and pending
matters within current estimates; (14) the ability to manage changes in applicable tax laws and regulations; (15) the ability to successfully manage our ongoing
acquisition, divestiture and joint venture activities, in each case to achieve the Company’s overall business strategy and financial objectives, without impacting
the delivery of base business objectives; (16) the ability to successfully achieve productivity improvements and cost savings and manage ongoing
organizational changes while successfully identifying, developing and retaining key employees, including in key growth markets where the availability of
skilled or experienced employees may be limited; (17) the ability to successfully manage the demand, supply and operational challenges, as well as
governmental responses or mandates, associated with a disease outbreak, including epidemics, pandemics or similar widespread public health concerns; (18)
the ability to manage the uncertainties, sanctions and economic effects from the war between Russia and Ukraine; and (19) the ability to successfully achieve
our ambition of reducing our greenhouse gas emissions and delivering progress towards our environmental sustainability priorities. A detailed discussion of
risks and uncertainties that could cause actual results and events to differ materially from those projected herein is included in the section titled "Economic
Conditions and Uncertainties" and the section titled "Risk Factors" (Part II, Item 1A) of this Form 10-Q.
Purpose, Approach and Non-GAAP Measures
The purpose of Management's Discussion and Analysis (MD&A) is to provide an understanding of Procter & Gamble's financial condition, results of
operations and cash flows by focusing on changes in certain key measures from year to year. The MD&A is provided as a supplement to, and should be read in
conjunction with, our Consolidated Financial Statements and accompanying Notes.
The MD&A is organized in the following sections:
• Overview
• Summary of Results – Nine Months Ended March 31, 2024
• Economic Conditions and Uncertainties
• Results of Operations – Three and Nine Months Ended March 31, 2024
• Segment Results – Three and Nine Months Ended March 31, 2024
• Liquidity and Capital Resources
• Measures Not Defined by U.S. GAAP
Throughout the MD&A we refer to measures used by management to evaluate performance, including unit volume growth, net sales, net earnings, diluted net
earnings per common share (diluted EPS) and operating cash flow. We also refer to a number of financial measures that are not defined under U.S. GAAP,
consisting of organic sales growth, Core earnings per share (Core EPS), adjusted free cash flow and adjusted free cash flow productivity. The explanation at the
end of the MD&A provides the definition of these non-GAAP measures, details on the use and the derivation of these measures, as well as reconciliations to
the most directly comparable U.S. GAAP measure.
Management also uses certain market share and market consumption estimates to evaluate performance relative to competition despite some limitations on the
availability and comparability of share and consumption information. References to market share and consumption in the MD&A are based on a combination
of vendor-purchased traditional brick-and-mortar and online data in key markets as well as internal estimates. All market share references represent the
percentage of sales of our products in dollar terms on a constant currency basis relative to all product sales in the category. The Company measures quarter and
fiscal year to date market shares through the most recent period for which market share data is available, which typically reflects a lag time of one or two
months as compared to the end of the reporting period. Management also uses unit volume growth to evaluate drivers of changes in net sales. Organic volume
growth reflects year-over-year changes in unit volume excluding the impacts of acquisitions and divestitures and certain one-time items, if applicable, and is
used to explain changes in organic sales. Certain columns and rows may not add due to rounding.
OVERVIEW
P&G is a global leader in the fast-moving consumer goods industry, focused on providing branded consumer packaged goods of superior quality and value to
our consumers around the world. Our products are sold in approximately 180 countries and territories, primarily through mass merchandisers, e-commerce
(including social commerce) channels, grocery stores, membership club stores, drug stores, department stores, distributors, wholesalers, specialty beauty stores
(including airport

-- 16 of 39 --

The Procter & Gamble Company 15
duty-free stores), high-frequency stores, pharmacies, electronics stores and professional channels. We also sell direct to individual consumers. We have on-the-
ground operations in approximately 70 countries.
Our market environment is highly competitive with global, regional and local competitors. In many of the markets and industry segments in which we sell our
products, we compete against other branded products as well as retailers' private-label brands. Additionally, many of the product segments in which we
compete are differentiated by price tiers (referred to as super-premium, premium, mid-tier and value-tier products). We believe we are well positioned in the
industry segments and markets in which we operate, often holding a leadership or significant market share position.
The table below lists our reportable segments, including the product categories and brand composition within each segment.
Reportable Segments 	Product Categories (Sub-Categories) 	Major Brands
Beauty
Hair Care (Conditioners, Shampoos, Styling Aids, Treatments) 	Head & Shoulders, Herbal
Essences, Pantene, Rejoice
Skin and Personal Care (Antiperspirants and Deodorants, Personal Cleansing, Skin
Care)
Olay, Old Spice, Safeguard,
Secret, SK-II
Grooming 	Grooming (Appliances, Female Blades & Razors, Male Blades & Razors, Pre- and
Post-Shave Products, Other Grooming) Braun, Gillette, Venus
Health Care
Oral Care (Toothbrushes, Toothpastes, Other Oral Care) 	Crest, Oral-B
Personal Health Care (Gastrointestinal, Pain Relief, Rapid Diagnostics, Respiratory,
Vitamins/Minerals/Supplements, Other Personal Health Care) Metamucil, Neurobion, Pepto-
Bismol, Vicks
Fabric & Home Care
Fabric Care (Fabric Enhancers, Laundry Additives, Laundry Detergents) 	Ariel, Downy, Gain, Tide
Home Care (Air Care, Dish Care, P&G Professional, Surface Care) Cascade, Dawn, Fairy, Febreze,
Mr. Clean, Swiffer
Baby, Feminine & Family Care
Baby Care (Baby Wipes, Taped Diapers and Pants) 	Luvs, Pampers
Feminine Care (Adult Incontinence, Feminine Care) Always, Always Discreet,
Tampax
Family Care (Paper Towels, Tissues, Toilet Paper) 	Bounty, Charmin, Puffs
Throughout the MD&A, we reference business results by region, which are comprised of North America, Europe, Greater China, Latin America, Asia Pacific
and India, Middle East and Africa (IMEA).
The following table provides the percentage of net sales and net earnings by reportable business segment (excluding Corporate) for the three and nine months
ended March 31, 2024:
Three Months Ended March 31, 2024 	Nine Months Ended March 31, 2024
Net Sales 	Net Earnings 	Net Sales 	Net Earnings
Beauty 	18 % 	16 % 	18 % 	18 %
Grooming 	8 % 	8 % 	8 % 	9 %
Health Care 	14 % 	14 % 	15 % 	15 %
Fabric & Home Care 	36 % 	35 % 	35 % 	34 %
Baby, Feminine & Family Care 	24 % 	27 % 	24 % 	24 %
Total Company 	100 % 	100 % 	100 % 	100 %
RECENT DEVELOPMENTS
Limited Market Portfolio Restructuring
In December 2023, the Company announced a limited market portfolio restructuring of its business operations, primarily in certain Enterprise Markets,
including Argentina and Nigeria, to address challenging macroeconomic and fiscal conditions. In connection with this announcement, the Company expects to
record incremental restructuring charges of $1.0 to $1.5 billion after tax, consisting primarily of foreign currency translation losses to be recognized as non-
cash charges upon the substantial liquidation of operations in the affected markets.
Although the timing of the completion of this restructuring program has yet to be determined, the Company currently anticipates that these restructuring
charges will be recognized in the fiscal years ending June 30, 2024 and 2025. Consistent with our historical policies for ongoing restructuring-type activities,
resulting charges will be funded by and included within Corporate for segment reporting. Restructuring charges above the normal ongoing level of
restructuring costs will be reported as non-core charges. For more details on the restructuring program, refer to Note 11 to the Consolidated Financial
Statements.

-- 17 of 39 --

16 The Procter & Gamble Company
Intangible Asset Impairment
During the three months ended December 31, 2023, the Company recorded a $1.3 billion before tax ($1.0 billion after tax) non-cash impairment charge, on
intangible assets acquired as part of the Company’s 2005 acquisition of The Gillette Company.
The impairment charge arose from a reduction in the estimated fair value of the Gillette indefinite-lived intangible asset due to a higher discount rate,
weakening of several currencies relative to the U.S. dollar and the impact of the non-core restructuring program described above. This impairment charge
adjusted the carrying value of the Gillette indefinite-lived intangible asset to fair value. For a more detailed discussion of the Gillette impairment, refer to Note
4 to the Consolidated Financial Statements.
SUMMARY OF RESULTS – Nine Months Ended March 31, 2024
The following are highlights of results for the nine months ended March 31, 2024, versus the nine months ended March 31, 2023:
• Net sales increased 3% to $63.5 billion versus the prior year period. Net sales increased mid-single digits in Health Care, Fabric & Home Care and
Grooming and low single digits in Beauty and Baby, Feminine & Family Care. Organic sales, which exclude the impacts of acquisitions and divestitures
and foreign exchange, increased 4%. Organic sales increased high single digits in Grooming, mid-single digits in Fabric & Home Care and Health Care
and low single digits in Baby, Feminine & Family Care and Beauty.
• Net earnings were $11.8 billion, an increase of $484 million, or 4%, versus the prior year period due to the increase in net sales, partially offset by the non-
cash impairment charge of $1.0 billion after taxes related to the Gillette intangible asset.
• Net earnings attributable to Procter & Gamble were $11.7 billion, an increase of $473 million, or 4%, versus the prior year period.
• Diluted EPS increased 5% to $4.75 due to the increase in net earnings. Core EPS, which excludes the charge for the Gillette intangible asset impairment
and incremental restructuring, increased 15% to $5.19.
• Operating cash flow was $14.1 billion. Adjusted free cash flow, which is defined as operating cash flow less capital expenditures and excluding payments
for the transitional tax resulting from the U.S. Tax Act, was $12.0 billion. Adjusted free cash flow productivity, which is defined as adjusted free cash flow
as a percentage of net earnings excluding the Gillette intangible asset impairment charge, was 93%.
ECONOMIC CONDITIONS AND UNCERTAINTIES
Global Economic Conditions. Our products are sold in numerous countries across North America, Europe, Latin America, Asia, Australia and Africa, with
more than half our sales generated outside the United States. Our largest international markets are Greater China, the United Kingdom, Canada, Japan and
Germany and collectively comprised more than 20% of our net sales in the fiscal year 2023. As such, we are exposed to and impacted by global
macroeconomic factors, geopolitical tensions, U.S. and foreign government policies and foreign exchange fluctuations. We are also exposed to market risks
from operating in challenging environments including unstable economic, political and social conditions, civil unrest, military conflicts, natural disasters, debt
and credit issues and currency controls or fluctuations. These risks can reduce our net sales or erode our operating margins and consequently reduce our net
earnings and cash flows.
Changes in Costs. Our costs are subject to fluctuations, particularly due to changes in commodity and input material prices, transportation costs, other broader
inflationary impacts and our own productivity efforts. We have significant exposures to certain commodities and input materials, in particular certain oil-
derived materials like resins and paper-based materials like pulp. Volatility in the market price of these commodities and input materials has a direct impact on
our costs. Disruptions in our manufacturing, supply and distribution operations due to energy shortages, natural disasters, labor or freight constraints could also
lead to increased costs. New or increased legal or regulatory requirements, along with initiatives to meet our sustainability goals, could also result in increased
costs due to higher material costs and investments in facilities and equipment. We strive to implement, achieve and sustain cost improvement plans, including
supply chain optimization and general overhead and workforce optimization. Increased pricing in response to certain inflationary or cost increases may also
offset portions of the cost impacts; however, such price increases may impact product consumption. If we are unable to manage cost impacts through pricing
actions and consistent productivity improvements, it may adversely impact our net sales, gross margin, operating margin, net earnings and cash flows.
Foreign Exchange. We have significant translation and transaction exposure to the fluctuation of exchange rates. Translation exposures relate to exchange rate
impacts of measuring income statements of foreign subsidiaries that do not use the U.S. dollar as their functional currency. Transaction exposures relate to 1)
the impact from input costs that are denominated in a currency other than the local reporting currency and 2) the revaluation of transaction-related working
capital balances denominated in currencies other than the functional currency. In the past three years, weakening of certain foreign currencies versus the U.S.
dollar has resulted in significant foreign exchange impacts leading to lower net sales, net earnings and cash flows. These fluctuations have significantly
impacted our historical net sales, net earnings and cash flows and could do so in the future. Certain countries that are currently experiencing significant
exchange rate fluctuations include Argentina, Russia and Turkey. Increased pricing in response to certain fluctuations in foreign currency exchange rates may
offset portions of the currency

-- 18 of 39 --

The Procter & Gamble Company 17
impacts but could also have a negative impact on the consumption of our products, which would negatively affect our net sales, gross margin, operating
margin, net earnings and cash flows.
Government Policies. Our net sales, gross margin, operating margin, net earnings and cash flows could be affected by changes in U.S. or foreign government
legislative, regulatory or enforcement policies. For example, our net earnings and cash flows could be affected by any future legislative or regulatory changes
in U.S. or non-U.S. tax policy, including changes resulting from the current work being led by the OECD/G20 Inclusive Framework focused on "Addressing
the Challenges of the Digitalization of the Economy." The breadth of the OECD project extends beyond pure digital businesses and is likely to impact most
large multinational businesses by both redefining jurisdictional taxation rights and establishing a 15% global minimum tax. Our net sales, gross margin,
operating margin, net earnings and cash flows may also be impacted by changes in U.S. and foreign government policies related to environmental and climate
change matters. Additionally, we attempt to carefully manage our debt, currency and other exposures in certain countries with currency exchange, import
authorization and pricing controls, such as Argentina, Egypt and Pakistan. Further, our net sales, gross margin, operating margin, net earnings and cash flows
could be affected by changes to international trade agreements in North America and elsewhere. Changes in government policies in the above areas might
cause an increase or decrease in our net sales, gross margin, operating margin, net earnings and cash flows.
Russia-Ukraine War. The war between Russia and Ukraine has negatively impacted our operations. Our Ukraine business includes two manufacturing sites
and accounted for less than 1% of consolidated net sales and consolidated net earnings in the fiscal year ended June 30, 2023. Net assets of our Ukraine
business accounted for less than 1% of consolidated net assets as of March 31, 2024. Our Russia business includes two manufacturing sites. Beginning in
March 2022, the Company reduced its product portfolio, discontinued new capital investments and suspended media, advertising and promotional activity in
Russia. The Russia business accounted for approximately 2% of consolidated net sales and consolidated net earnings in the fiscal year ended June 30, 2023.
Net assets of our Russia business accounted for less than 2% of consolidated net assets as of March 31, 2024.
Future impacts to the Company are difficult to predict due to the high level of uncertainty related to the war’s duration, evolution and ultimate resolution.
Within Ukraine, there is a possibility of physical damage and destruction of our two manufacturing facilities. We may not be able to operate our manufacturing
sites and source raw materials from our suppliers or ship finished products to our customers.
Within Russia, we may not be able to continue our reduced operations at current levels due to sanctions and counter-sanctions, monetary, currency or payment
controls, legislative restrictions or policies, restrictions on access to financial institutions and supply and transportation challenges. Our suppliers, distributors
and retail customers are also impacted by the war and their ability to successfully maintain their operations could also impact our operations or negatively
impact the sales of our products.
More broadly, there could be additional negative impacts to our net sales, earnings and cash flows should the situation escalate beyond its current scope,
including, among other potential impacts, economic recessions in certain neighboring countries or globally due to inflationary pressures and supply chain cost
increases or the geographic proximity of the war relative to the rest of Europe.
For additional information on risk factors that could impact our business results, please refer to Risk Factors in Part I, Item 1A of the Company's Form 10-K for
the fiscal year ended June 30, 2023.

-- 19 of 39 --

18 The Procter & Gamble Company
RESULTS OF OPERATIONS – Three Months Ended March 31, 2024
The following discussion provides a review of results for the three months ended March 31, 2024, versus the three months ended March 31, 2023.
Three Months Ended March 31
Amounts in millions, except per share amounts 	2024 	2023 	% Chg
Net sales 	$ 	20,195 $ 	20,068 	1%
Operating income 	4,460 	4,248 	5%
Earnings before income taxes 	4,592 	4,288 	7%
Net earnings 	3,781 	3,424 	10%
Net earnings attributable to Procter & Gamble 	3,754 	3,397 	11%
Diluted net earnings per common share 	1.52 	1.37 	11%
Core net earnings per common share 	1.52 	1.37 	11%
Three Months Ended March 31
COMPARISONS AS A PERCENTAGE OF NET SALES 	2024 	2023 	Basis Pt Chg
Gross margin 	51.2 % 	48.2 % 	300
Selling, general & administrative expense 	29.1 % 	27.0 % 	210
Operating income 	22.1 % 	21.2 % 	90
Earnings before income taxes 	22.7 % 	21.4 % 	130
Net earnings 	18.7 % 	17.1 % 	160
Net earnings attributable to Procter & Gamble 	18.6 % 	16.9 % 	170
Net Sales
Net sales for the quarter increased 1% to $20.2 billion. The increase in net sales was due to increased pricing of 3%, partially offset by unfavorable foreign
exchange of 2%. Unit volume and mix had a neutral impact on net sales growth. Excluding the impact of acquisitions and divestitures and foreign exchange,
organic sales increased 3%.
The following table summarizes key drivers of the change in net sales by reportable segment:
Net Sales Change Drivers 2024 vs. 2023 (Three Months Ended March 31)
Volume with
Acquisitions &
Divestitures
Volume Excluding
Acquisitions &
Divestitures
Foreign
Exchange 	Price 	Mix 	Other
Net Sales
Growth
Beauty 	1 % 	1 % 	(3) % 	4 % 	(1) % 	1 % 	2 %
Grooming 	2 % 	2 % 	(7) % 	10 % 	(1) % 	(1) % 	3 %
Health Care 	(4) % 	(4) % 	(1) % 	4 % 	3 % 	— % 	2 %
Fabric & Home Care 	1 % 	1 % 	(1) % 	2 % 	— % 	— % 	2 %
Baby, Feminine & Family Care 	(3) % 	(3) % 	(2) % 	2 % 	1 % 	— % 	(2) %
Total Company 	— % 	— % 	(2)% 	3 % 	— % 	— % 	1 %
Net sales percentage changes are approximations based on quantitative formulas that are consistently applied.
Other includes the sales mix impact from acquisitions and divestitures and rounding impacts necessary to reconcile volume to net sales.
Operating Costs
Gross margin increased 300 basis points to 51.2% of net sales for the quarter. The increase in gross margin was due to:
• 260 basis points of manufacturing productivity savings,
• 130 basis points of lower commodity costs and
• a 130 basis-point increase due to higher pricing.
These impacts were partially offset by:
• a 100 basis-point decline from unfavorable product mix including the decline of the super-premium SK-II brand,
• a 90 basis-point decline from unfavorable foreign exchange impacts and
• 30 basis points of product and packaging investments.
(1)
(2)
(1)
(2)

-- 20 of 39 --

The Procter & Gamble Company 19
Total SG&A spending increased 9% to $5.9 billion versus the prior year period due to increased marketing spending and overhead costs. SG&A as a percentage
of net sales increased 210 basis points to 29.1% due to the increase in marketing and overhead spending as a percentage of net sales. Marketing spending as a
percentage of net sales increased 180 basis points as the increase in marketing spending was partially offset by the positive scale impacts of the net sales
increase and productivity savings. Overhead costs as a percentage of net sales increased 50 basis points as wage inflation, foreign exchange and other cost
increases were offset by the positive scale impacts of the net sales increase and productivity savings. Other operating expenses as a percentage of net sales
decreased 20 basis points. Productivity-driven cost savings delivered 60 basis points of benefit to SG&A as a percentage of net sales.
Non-Operating Expenses and Income
Interest expense was $233 million for the quarter, an increase of $11 million versus the prior year period due primarily to higher interest rates. Interest income
was $104 million for the quarter, an increase of $21 million versus the prior year period due primarily to higher interest rates. Other non-operating income was
$260 million, which is an increase of $81 million versus the prior year period due to gains from the sale of minor brands.
Income Taxes
The effective income tax rate for the three months ended March 31, 2024, was 17.7%, compared to 20.1% for the three months ended March 31, 2023. The
decrease in the effective tax rate was primarily driven by a 160 basis-point decrease from higher excess tax benefits of share-based compensation and decreases
from discrete impacts related to uncertain tax positions.
Net Earnings
Operating income increased $212 million, or 5%, to $4.5 billion for the quarter, due to the increase in net sales and the increase in operating margin, the
components of which are discussed above.
Net earnings increased $357 million, or 10%, to $3.8 billion due to the increase in operating income, increase in non-operating income and a decrease in the
effective tax rate. Foreign exchange had a negative impact of approximately $220 million on net earnings for the quarter, including both transactional and
translational impacts from converting earnings from foreign subsidiaries to U.S. dollars. Net earnings attributable to Procter & Gamble increased $357 million,
or 11%, to $3.8 billion for the quarter. Diluted EPS increased 11% to $1.52 versus the prior year period due to the increase in net earnings.
RESULTS OF OPERATIONS – Nine Months Ended March 31, 2024
The following discussion provides a review of results for the nine months ended March 31, 2024, versus the nine months ended March 31, 2023.
Nine Months Ended March 31
Amounts in millions, except per share amounts 	2024 	2023 	% Chg
Net sales 	$ 	63,507 $ 	61,453 	3%
Operating income 	14,660 	13,972 	5%
Earnings before income taxes 	14,891 	14,120 	5%
Net earnings 	11,830 	11,346 	4%
Net earnings attributable to Procter & Gamble 	11,742 	11,269 	4%
Diluted net earnings per common share 	4.75 	4.53 	5%
Core net earnings per common share 	5.19 	4.53 	15%
Nine Months Ended March 31
COMPARISONS AS A PERCENTAGE OF NET SALES 	2024 	2023 	Basis Pt Chg
Gross margin 	52.0 % 	47.7 % 	430
Selling, general & administrative expense 	26.8 % 	25.0 % 	180
Operating income 	23.1 % 	22.7 % 	40
Earnings before income taxes 	23.4 % 	23.0 % 	40
Net earnings 	18.6 % 	18.5 % 	10
Net earnings attributable to Procter & Gamble 	18.5 % 	18.3 % 	20
Net Sales
Net sales for the period increased 3% to $63.5 billion. The increase in net sales was due to higher pricing of 5%, partially offset by unfavorable foreign
exchange of 1%. Unit volume and mix were unchanged. Excluding the impact of acquisitions and divestitures and foreign exchange, organic sales increased
4%.

-- 21 of 39 --

20 The Procter & Gamble Company
The following table summarizes key drivers of the change in net sales by reportable segment:
Net Sales Change Drivers 2024 vs. 2023 (Nine Months Ended March 31)
Volume with
Acquisitions &
Divestitures
Volume Excluding
Acquisitions &
Divestitures
Foreign
Exchange 	Price 	Mix 	Other
Net Sales
Growth
Beauty 	1 % 	— % 	(2) % 	5 % 	(2) % 	— % 	2 %
Grooming 	— % 	— % 	(4) % 	8 % 	1 % 	— % 	5 %
Health Care 	(2) % 	(2) % 	1 % 	5 % 	2 % 	— % 	6 %
Fabric & Home Care 	— % 	1 % 	(1) % 	4 % 	1 % 	1 % 	5 %
Baby, Feminine & Family Care 	(3) % 	(3) % 	(2) % 	5 % 	1 % 	— % 	1 %
Total Company 	— % 	— % 	(1)% 	5 % 	— % 	(1)% 	3 %
Net sales percentage changes are approximations based on quantitative formulas that are consistently applied.
Other includes the sales mix impact from acquisitions and divestitures and rounding impacts necessary to reconcile volume to net sales.
Operating Costs
Gross margin increased 430 basis points to 52.0% of net sales for the period. The increase in gross margin was due to:
• a 220 basis-point increase due to higher pricing,
• 220 basis points of manufacturing productivity savings and
• 180 basis points of lower commodity costs.
These impacts were partially offset by:
• a 70 basis-point decline from unfavorable foreign exchange impacts,
• a 60 basis-point decline from unfavorable product mix including the decline of the super-premium SK-II brand,
• 30 basis points of product and packaging investments and
• 30 basis points of one-time manufacturing related costs including capacity startup costs.
Total SG&A spending increased 11% to $17.0 billion versus the prior year period due to increased marketing spending and overhead costs. SG&A as a
percentage of net sales increased 180 basis points to 26.8% due to the increase in marketing spending and overhead spending as a percentage of sales.
Marketing spending as a percentage of net sales increased 150 basis points as the increase in marketing spending was partially offset by the positive scale
impacts of the net sales increase and productivity savings. Overhead costs as a percentage of net sales increased 20 basis points due to wage inflation and other
cost increases, partially offset by the positive scale impacts of the net sales increase and productivity savings. Other operating expenses as a percentage of net
sales increased 10 basis points. Productivity-driven cost savings delivered 80 basis points of benefit to SG&A as a percentage of net sales.
In the period ended December 31, 2023, the Company recorded a non-cash impairment charge of $1.3 billion ($1.0 billion after tax) on the Gillette intangible
asset. The impairment charge arose from a reduction in the estimated fair value of the Gillette indefinite-lived intangible asset due to a higher discount rate,
weakening of several currencies relative to the U.S. dollar and the impact of the limited market portfolio restructuring program. For further discussion of the
Gillette impairment charge, refer to Note 4 to the Consolidated Financial Statements.
Non-Operating Expenses and Income
Interest expense was $705 million for the period, an increase of $189 million versus the prior year period due primarily to higher interest rates. Interest income
was $366 million for the period, an increase of $175 million versus the prior year period due primarily to higher interest rates. Other non-operating income was
$570 million, which is an increase of $97 million versus the prior year period, due primarily to gains from the sale of minor brands and an increase in net non-
operating benefits on postretirement plans.
Income Taxes
The effective income tax rate for the nine months ended March 31, 2024, was 20.6%, compared to 19.6% for the nine months ended March 31, 2023. The
increase in the effective tax rate was primarily due to the net impacts of the prior year recognition of operating loss carryforwards, partially offset by decreases
due to higher excess tax benefits of share-based compensation.
Net Earnings
Operating income increased $688 million, or 5%, to $14.7 billion for the period, due to the increase in net sales and the increase in gross margin, the
components of which are described above. These benefits were partially offset by non-cash before tax impairment charges of $1.3 billion related to the Gillette
intangible asset and an increase in SG&A spending as a percentage of net sales.
(1)
(2)
(1)
(2)

-- 22 of 39 --

The Procter & Gamble Company 21
Net earnings increased $484 million, or 4%, to $11.8 billion, as the increase in operating income was partially offset by an increase in the effective tax rate.
Foreign exchange had a negative impact of approximately $468 million on net earnings for the period, including both transactional and translational impacts
from converting earnings from foreign subsidiaries to U.S. dollars. Net earnings attributable to Procter & Gamble increased $473 million, or 4%, to $11.7
billion for the period. Diluted EPS increased 5% to $4.75 versus the prior year period due to the increase in net earnings and a reduction in the weighted
average number of shares outstanding. Core EPS, which represents diluted EPS excluding charges for incremental restructuring and the impairment of the
Gillette intangible asset, increased 15% to $5.19.
SEGMENT RESULTS – Three and Nine Months Ended March 31, 2024
The following discussion provides a review of results by reportable business segment. Analysis of the results for the three and nine months ended March 31,
2024, is provided based on a comparison to the three and nine months ended March 31, 2023. The primary financial measures used to evaluate segment
performance are net sales and net earnings. The table below provides supplemental information on net sales, earnings before income taxes and net earnings by
reportable business segment for the three and nine months ended March 31, 2024, versus the comparable prior year period (dollar amounts in millions):
Three Months Ended March 31, 2024
Net Sales
% Change
Versus Year Ago
Earnings/(Loss) Before
Income Taxes
% Change
Versus Year Ago 	Net Earnings/(Loss)
% Change
Versus Year Ago
Beauty 	$ 	3,550 	2 % $ 	753 	(1) % $ 	587 	(3) %
Grooming 	1,539 	3 % 	379 	(1) % 	303 	(2) %
Health Care 	2,873 	2 % 	687 	3 % 	525 	— %
Fabric & Home Care 	7,169 	2 % 	1,692 	10 % 	1,301 	11 %
Baby, Feminine & Family Care 	4,936 	(2) % 	1,299 	8 % 	997 	8 %
Corporate 	128 	N/A 	(218) 	N/A 	68 	N/A
Total Company 	$ 	20,195 	1 % $ 	4,592 	7 % $ 	3,781 	10 %
Nine Months Ended March 31, 2024
Net Sales % Change
Versus Year Ago Earnings/(Loss) Before
Income Taxes % Change
Versus Year Ago 	Net Earnings/(Loss) % Change
Versus Year Ago
Beauty 	$ 	11,496 	2 % $ 	3,114 	(2) % $ 	2,426 	(4) %
Grooming 	4,997 	5 % 	1,450 	5 % 	1,165 	4 %
Health Care 	9,119 	6 % 	2,508 	7 % 	1,933 	6 %
Fabric & Home Care 	22,230 	5 % 	5,741 	24 % 	4,446 	26 %
Baby, Feminine & Family Care 	15,268 	1 % 	4,144 	23 % 	3,174 	23 %
Corporate 	398 	N/A 	(2,066) 	N/A 	(1,314) 	N/A
Total Company 	$ 	63,507 	3 % $ 	14,891 	5 % $ 	11,830 	4 %
Beauty
Three months ended March 31, 2024, compared with three months ended March 31, 2023
Beauty net sales increased 2% to $3.6 billion as the positive impacts of higher pricing of 4%, unit volume increase of 1% and benefit from acquisitions of 1%
were partially offset by the negative impacts of unfavorable foreign exchange of 3% and unfavorable mix of 1% (due primarily to the decline of the super-
premium SK-II brand, which has higher than segment-average selling prices). Excluding the impact of acquisitions and divestitures and foreign exchange,
organic sales increased 3%. Global market share of the Beauty segment decreased 0.2 points.
• Hair Care net sales increased mid-single digits. Positive impacts of higher pricing (driven by Argentina, Europe and North America), a benefit from
acquisitions and favorable geographic and brand mix (due to growth of the premium Native brand) were partially offset by negative impacts of unfavorable
foreign exchange. Unit volume was unchanged as growth in North America (due to increased marketing support and distribution gains) and Latin America
(due to market growth) was offset by a decline in IMEA (due to increased pricing and lower demand in the Middle East). Organic sales increased high
single digits driven by more than 30% growth in Latin America, a double-digit increase in Europe and a high single-digit increase in North America,
partially offset by a mid-single-digit decrease in Greater China. Global market share of the Hair Care category decreased 0.5 points.
• Skin and Personal Care net sales decreased low single digits. Negative impacts of unfavorable mix (due to the decline of the super-premium SK-II brand,
which has higher than category-average selling prices) and unfavorable foreign exchange

-- 23 of 39 --

22 The Procter & Gamble Company
were partially offset by an increase in unit volume and higher pricing (across all regions). The volume increase was driven by growth in North America
(due to innovation in Personal Care) and Latin America (due to market growth). Organic sales decreased low single digits due to a 20% decline in Greater
China, partially offset by high single-digit growth in North America. Global market share of the Skin and Personal Care category increased 0.1 points.
Net earnings decreased 3% to $587 million as the increase in net sales was more than offset by a 90 basis-point decline in net earnings margin. Net earnings
margin decreased as an increase in gross margin was more than fully offset by an increase in SG&A as a percentage of net sales and a higher effective tax rate.
The gross margin improvement was driven by increased productivity savings and pricing, partially offset by negative product mix (due to the decline of the
super-premium SK-II brand) and unfavorable foreign exchange impacts. SG&A as a percentage of net sales increased due primarily to an increase in marketing
and overhead spending, partially offset by the positive scale effects of the net sales increase. The higher effective tax rate was driven by unfavorable geographic
mix.
Nine months ended March 31, 2024, compared with nine months ended March 31, 2023
Beauty net sales increased 2% to $11.5 billion, as the positive impacts of higher pricing of 5% and a unit volume increase of 1% were partially offset by the
negative impacts of unfavorable foreign exchange of 2% and unfavorable mix of 2% (due primarily to the decline of the super-premium SK-II brand, which has
higher than segment-average selling prices). Excluding the impact of acquisitions and divestitures and foreign exchange, organic sales increased 3%. Global
market share of the Beauty segment increased 0.1 points.
• Hair Care net sales increased high single digits. Positive impacts of higher pricing (driven by Latin America, Europe and North America), a benefit from
acquisitions and favorable brand mix (due to growth of the premium Native brand) were partially offset by negative impacts of unfavorable foreign
exchange. Unit volume was unchanged as growth in North America (due to innovation) and Latin America (due to market growth) was offset by a decline
in Greater China (due to market contraction and distribution footprint changes). Organic sales increased high single digits due to a more than 30% growth
in Latin America, low teens increase in Europe and double-digit increase in North America, partially offset by a high single-digit decline in Greater China.
Global market share of the Hair Care category decreased 0.4 points.
• Skin and Personal Care net sales decreased low single digits. Negative impacts of unfavorable mix (due to the decline of the super-premium SK-II brand,
which has higher than category-average selling prices) and unfavorable foreign exchange were partially offset by the positive impacts of higher pricing
(across all regions) and an increase in unit volume. The increase in volume was driven by growth in North America and Europe (both due to innovation in
Personal Care), partially offset by a decline in Greater China (due to the decline of the super-premium SK-II brand and market contraction). Organic sales
decreased low single digits, due to a high-teens decline in Asia Pacific and a mid-teens decline in Greater China, partially offset by a double-digit increase
in North America. Global market share of the Skin and Personal Care category increased 0.3 points.
Net earnings decreased 4% to $2.4 billion, as the increase in net sales was more than offset by a 140 basis-point decline in net earnings margin. Net earnings
margin decreased as an increase in gross margin was more than fully offset by an increase in SG&A as a percentage of net sales and a higher effective tax rate.
The gross margin improvement was driven by increased pricing and productivity savings, partially offset by negative product mix (due to the decline of the
super-premium SK-II brand) and unfavorable foreign exchange impacts. SG&A as a percentage of net sales increased due primarily to an increase in marketing
and overhead spending and higher foreign exchange transactional charges, partially offset by the positive scale effects of the net sales increase. The higher
effective tax rate was driven by unfavorable geographic mix.
Grooming
Three months ended March 31, 2024, compared with three months ended March 31, 2023
Grooming net sales increased 3% to $1.5 billion as the benefits of higher pricing of 10% (driven primarily by Argentina and Europe) and a 2% increase in unit
volume were partially offset by unfavorable foreign exchange of 7% and unfavorable product mix of 1% (due to the disproportionate growth of disposables).
The volume growth was driven primarily by Latin America and IMEA (both due to innovation), partially offset by a decline in Greater China (due to market
contraction). Excluding the impact of acquisitions and divestitures and foreign exchange, organic sales increased 10% driven by a more than 50% growth in
Latin America and double-digit growth in Europe, partially offset by a low single-digit decline in North America. Global market share of the Grooming
segment increased 0.7 points.
Net earnings decreased 2% to $303 million as the net sales growth was more than fully offset by a 90 basis-point decrease in net earnings margin. Net earnings
margin decreased as an increase in gross margin was more than fully offset by an increase in SG&A as a percentage of net sales. The gross margin increase was
driven by higher pricing and productivity savings, partially offset by unfavorable foreign exchange and unfavorable mix due to the growth of premium
innovation that has lower than segment-average gross margins. SG&A as a percentage of net sales increased due primarily to an increase in marketing
spending, partially offset by the positive scale effects of the net sales increase.

-- 24 of 39 --

The Procter & Gamble Company 23
Nine months ended March 31, 2024, compared with nine months ended March 31, 2023
Grooming net sales increased 5% to $5.0 billion as the benefits of higher pricing of 8% (driven primarily by Latin America and Europe) and favorable product
mix (due to growth of premium shavers) of 1% were partially offset by unfavorable foreign exchange of 4%. Unit volume was unchanged as growth in Latin
America and IMEA (both due to innovation) was offset by declines in Europe (due to increased pricing) and Greater China (due to market decline and
increased pricing). Excluding the impact of acquisitions and divestitures and foreign exchange, Grooming organic sales increased 9% due to more than 30%
growth in Latin America and double-digit growth in Europe, partially offset by a low single-digit decline in North America. Global market share of the
Grooming segment increased 0.5 points.
Net earnings increased 4% to $1.2 billion, due to the net sales growth. Net earnings margin was unchanged as an increase in gross margin was fully offset by an
increase in SG&A as a percentage of net sales. The gross margin increase was driven by higher pricing and productivity savings, partially offset by unfavorable
foreign exchange. SG&A as a percentage of net sales increased due to an increase in marketing spending and higher foreign exchange transactional charges,
partially offset by the positive scale effects of the net sales increase.
Health Care
Three months ended March 31, 2024, compared with three months ended March 31, 2023
Health Care net sales increased 2% to $2.9 billion driven by higher pricing of 4% and favorable product mix of 3%, partially offset by a 4% decrease in unit
volume and unfavorable foreign exchange of 1%. Excluding the impact of acquisitions and divestitures and foreign exchange, organic sales also increased 2%.
Global market share of the Health Care segment increased 0.7 points.
• Oral Care net sales increased low single digits driven by the positive impacts of favorable product mix (due to growth of power brushes and premium
paste, which have higher than category-average selling prices) partially offset by a decline in unit volume and unfavorable foreign exchange impacts. The
decrease in unit volume was driven primarily by declines in Latin America (due to increased pricing and competitive activity), North America and Asia
Pacific (both due to share losses). Organic sales increased mid-single digits driven by a double-digit increase in Europe and a low single-digit increase in
North America, partially offset by a double-digit decrease in Asia Pacific. Global market share of the Oral Care category increased 0.3 points.
• Personal Health Care net sales were unchanged as the positive impacts of higher pricing (driven by Argentina and North America) were fully offset by a
decrease in unit volume, unfavorable foreign exchange and unfavorable product mix (due to the decline of respiratory products, which have higher than
category-average selling prices). The volume decrease was driven primarily by declines in IMEA (due to distribution rationalization), North America (due
to market decline of respiratory products) and Latin America (due to market contraction). Organic sales increased low single digits driven by mid-single-
digit growth in Latin America and low single-digit growth in North America, partially offset by a high single-digit decline in IMEA. Global market share
of the Personal Health Care category increased 0.8 points.
Net earnings were unchanged at $525 million as the net sales growth was fully offset by a 20 basis-point decrease in net earnings margin. Net earnings margin
decreased as an increase in gross margin was more than fully offset by an increase in SG&A as a percentage of net sales and a higher effective tax rate. The
gross margin increase was driven by higher pricing and productivity savings, partially offset by unfavorable product mix (due to a decline in respiratory
products, which have higher than segment-average gross margins) and unfavorable foreign exchange. SG&A as a percentage of net sales increased due to
increased marketing and overhead spending, partially offset by the positive scale impacts of the net sales increase and a decrease in other operating costs. The
higher effective tax rate was driven by unfavorable geographic mix.
Nine months ended March 31, 2024, compared with nine months ended March 31, 2023
Health Care net sales increased 6% to $9.1 billion driven by higher pricing of 5%, favorable geographic and product mix of 2% and favorable foreign exchange
of 1%, partially offset by a 2% decrease in unit volume. Excluding the impact of acquisitions and divestitures and foreign exchange, organic sales increased
5%. Global market share of the Health Care segment increased 0.7 points.
• Oral Care net sales increased mid-single digits due to the positive impacts of favorable product mix (due to growth of premium paste and power brushes,
which have higher than category-average selling prices), higher pricing (driven by Europe, North America and Latin America) and favorable foreign
exchange, partially offset by a decrease in unit volume. The unit volume decrease was due to a decline in Latin America (due to share losses) and Asia
Pacific (due to increased pricing) partially offset by growth in Europe (due to market growth). Organic sales also increased mid-single digits due to a
double-digit increase in Europe and a mid-single-digit increase in North America. Global market share of the Oral Care category increased 0.3 points.
• Personal Health Care net sales increased mid-single digits due to the positive impacts of higher pricing (driven by North America, Latin America and
Europe) and favorable foreign exchange, partially offset by a decline in unit volume and unfavorable mix (due to the decline of respiratory products, that
have higher than category-average selling prices). The decline in unit volume was driven by declines in IMEA, Asia Pacific and Latin America (all due to
market contraction

-- 25 of 39 --

24 The Procter & Gamble Company
including lower cough and cold incidence), partially offset by growth in North America (due to innovation). Organic sales increased mid-single digits due
to mid-single-digit growth in North America and low single-digit growth in Europe. Global market share of the Personal Health Care category increased
0.8 points.
Net earnings increased 6% to $1.9 billion due to the increase in net sales. Net earnings margin was unchanged as an increase in gross margin was offset by an
increase in SG&A as a percentage of net sales and a higher effective tax rate. The gross margin increase was driven by higher pricing and productivity savings,
partially offset by unfavorable product mix (due to a decline in respiratory and whitening products, both of which have higher than segment-average gross
margins). SG&A as a percentage of net sales increased due to increased marketing and overhead spending, partially offset by the positive scale impacts of the
net sales increase. The higher effective tax rate was driven by unfavorable geographic mix.
Fabric & Home Care
Three months ended March 31, 2024, compared with three months ended March 31, 2023
Fabric & Home Care net sales increased 2% to $7.2 billion driven by higher pricing of 2% and a unit volume increase of 1%, partially offset by unfavorable
foreign exchange of 1%. Excluding the impact of foreign exchange and acquisitions and divestitures, organic sales increased 3%. Global market share of the
Fabric & Home Care segment decreased 0.1 points.
• Fabric Care net sales were unchanged as the positive impacts of higher pricing (driven primarily by Asia Pacific and Europe, partially offset by increased
trade spending in North America) and favorable geographic mix were partially offset by unfavorable foreign exchange. Volume was unchanged as growth
in North America was fully offset by declines in Asia Pacific (due to share losses) and IMEA (due to lower demand in the Middle East and increased
pricing). Organic sales increased low single digits driven by a mid-single-digit increase in North America and a high single-digit increase in Europe,
partially offset by a double-digit decrease in IMEA. Global market share of the Fabric Care category decreased 0.5 points.
• Home Care net sales increased mid-single digits. Positive impacts of a unit volume increase, higher pricing (driven primarily by Europe) and favorable
premium product mix were partially offset by unfavorable foreign exchange. The increase in unit volume was due primarily to growth in North America
(due to innovation) and Europe (due to increased marketing support), partially offset by a decline in Latin America (due to increased pricing). Organic
sales increased high single digits driven by high single-digit growth in North America and mid-teens growth in Europe. Global market share of the Home
Care category increased 0.5 points.
Net earnings increased 11% to $1.3 billion due to the increase in net sales and a 140 basis-point improvement in net earnings margin. Net earnings margin
increased due to an increase in gross margin partially offset by an increase in SG&A as a percentage of net sales. The gross margin increase was driven by
increased productivity savings, lower commodity costs and higher pricing, partially offset by unfavorable mix due to the growth of premium products that have
lower than segment-average gross margins. SG&A as a percentage of net sales increased due to an increase in marketing spending, partially offset by the
positive scale effects of the net sales increase.
Nine months ended March 31, 2024, compared with nine months ended March 31, 2023
Fabric & Home Care net sales increased 5% to $22.2 billion driven by higher pricing of 4% and favorable product mix of 1%, partially offset by unfavorable
foreign exchange of 1%. Unit volume was unchanged. Excluding the impact of foreign exchange and acquisitions and divestitures, organic sales increased 6%.
Global market share of the Fabric & Home Care segment increased 0.2 points.
• Fabric Care net sales increased mid-single digits driven by the positive impacts of higher pricing (driven by Europe, Asia Pacific and Latin America) and
favorable geographic mix. Unit volume was unchanged as growth in North America (due to market growth) was offset by declines in Asia Pacific (due to
increased pricing) and Greater China (due to market contraction and portfolio rationalization). Organic sales also increased mid-single digits driven by a
double-digit increase in Europe and a mid-single-digit increase in North America. Global market share of the Fabric Care category decreased 0.3 points.
• Home Care net sales increased high single digits. Positive impacts of higher pricing (driven primarily by Europe, North America and Latin America),
favorable premium product mix and a unit volume increase were partially offset by unfavorable foreign exchange. The increase in volume was due to
growth in North America (due to innovation), partially offset by decline in Latin America (due to increased pricing). Organic sales increased double digits
driven by mid-teens growth in Europe and high single-digit growth in North America. Global market share of the Home Care category increased 0.9
points.
Net earnings increased 26% to $4.4 billion due to the increase in net sales and a 340 basis-point improvement in net earnings margin. Net earnings margin
increased due to an increase in gross margin, partially offset by an increase in SG&A as a percentage of net sales. The gross margin increase was driven by
higher pricing, increased productivity savings and lower commodity costs. SG&A as a percentage of net sales increased due to an increase in marketing
spending, partially offset by the positive scale effects of the net sales increase.

-- 26 of 39 --

The Procter & Gamble Company 25
Baby, Feminine & Family Care
Three months ended March 31, 2024, compared with three months ended March 31, 2023
Baby, Feminine & Family Care net sales decreased 2% to $4.9 billion due to a 3% decrease in unit volume and unfavorable foreign exchange of 2% partially
offset by higher pricing of 2% and favorable mix of 1%. Excluding the impacts of foreign exchange and acquisitions and divestitures, organic sales were
unchanged. Global market share of the Baby, Feminine & Family Care segment decreased 0.1 points.
• Baby Care net sales decreased high single digits. Negative impacts of a decrease in unit volume and unfavorable foreign exchange were partially offset by
higher pricing (primarily driven by Argentina) and favorable product mix (due to a higher proportion of premium diapers, which have higher than
category-average selling prices). The unit volume decline was due primarily to Europe (due to higher pricing), North America (due to market decline and
competitive activity) and IMEA (due to lower demand in the Middle East and increased pricing). Organic sales decreased mid-single digits as a high
single-digit decline in Europe and mid-single-digit decline in North America were partially offset by a more than 20% growth in Latin America. Global
market share of the Baby Care category decreased 0.2 points.
• Feminine Care net sales increased low single digits. Positive impacts of higher pricing (driven primarily by Europe) and favorable mix (due to growth of
premium products) were partially offset by a decrease in unit volume and unfavorable foreign exchange. The volume decrease was primarily driven by
declines in Europe and Latin America (both due to increased pricing). Organic sales increased low single digits driven by an approximately 20% increase
in Latin America and a low single-digit increase in Europe. Global market share of the Feminine Care category was unchanged.
• Net sales in Family Care, which is predominantly a North America business, increased low single digits driven by an increase in unit volume, partially
offset by unfavorable product mix (due to growth of larger pack sizes with lower than category-average selling prices). Organic sales also increased low
single digits. North America market share of the Family Care category decreased 0.1 points.
Net earnings increased 8% to $997 million as the decrease in net sales was more than fully offset by a 190 basis-point increase in net earnings margin. Net
earnings margin increased primarily due to an increase in gross margin, partially offset by an increase in SG&A as a percentage of net sales. Gross margin
increased primarily due to increased productivity savings, lower commodity costs and increased pricing, partially offset by unfavorable foreign exchange.
SG&A as a percentage of net sales increased due to an increase in marketing and overhead spending.
Nine months ended March 31, 2024, compared with nine months ended March 31, 2023
Baby, Feminine & Family Care net sales increased 1% to $15.3 billion driven by higher pricing of 5% and favorable product mix of 1%, partially offset by a
3% decrease in unit volume and unfavorable foreign exchange of 2%. Excluding the impacts of foreign exchange and acquisitions and divestitures, organic
sales increased 3%. Global market share of the Baby, Feminine & Family Care segment decreased 0.1 points.
• Baby Care net sales decreased low single digits. Negative impacts of a decrease in unit volume and unfavorable foreign exchange were partially offset by
higher pricing (driven primarily by Latin America and Europe) and favorable product mix (due to growth of premium diapers, which have higher than
category-average selling prices). Volumes decreased in all regions led by Europe and North America, due to increased pricing and competitive activity.
Organic sales increased low single digits driven by more than 20% growth in Latin America, partially offset by a mid-single-digit decline in Europe.
Global market share of the Baby Care category decreased 0.2 points.
• Feminine Care net sales increased low single digits. Positive impacts of higher pricing (driven primarily by Europe, IMEA and Latin America) and
favorable mix (due to growth of premium products) were partially offset by a decrease in unit volume and unfavorable foreign exchange. The volume
decrease was driven primarily by declines in Europe and IMEA (both due to increased pricing), partially offset by growth in North America (due to
increased marketing support and distribution gains). Organic sales increased mid-single digits driven by high single-digit increases in Europe and IMEA
and a mid-single-digit increase in North America. Global market share of the Feminine Care category increased 0.3 points.
• Net sales in Family Care, which is predominantly a North America business, increased mid-single digits driven by higher pricing and a unit volume
increase, partially offset by unfavorable product mix (due to growth of larger pack sizes with lower than category-average selling prices). Organic sales
also increased mid-single digits. North America market share of the Family Care category decreased 0.2 points.
Net earnings increased 23% to $3.2 billion due to the increase in net sales and a 370 basis-point increase in net earnings margin. Net earnings margin increased
primarily due to an increase in gross margin, partially offset by an increase in SG&A as a percentage of net sales. Gross margin increased primarily due to
lower commodity costs, increased pricing and increased productivity savings, partially offset by unfavorable foreign exchange. SG&A as a percentage of net
sales increased due to an increase in marketing and overhead spending, partially offset by the positive scale impacts of the net sales increase.

-- 27 of 39 --

26 The Procter & Gamble Company
Corporate
Corporate includes certain operating and non-operating activities not allocated to specific business segments. These include but are not limited to incidental
businesses managed at the corporate level, gains and losses related to certain divested brands or businesses, impacts from various financing and investing
activities, impacts related to employee benefits, asset impairments and restructuring activities including manufacturing and workforce optimization. Corporate
also includes reconciling items to adjust the accounting policies used within the reportable segments to U.S. GAAP. The most notable ongoing reconciling item
is income taxes, which adjusts the blended statutory rates that are reflected in the reportable segments to the overall Company effective tax rate.
For the three months ended March 31, 2024, Corporate net sales decreased $45 million to $128 million due to a decrease in net sales of incidental businesses
managed at the corporate level. Corporate net earnings increased $182 million to $68 million for the quarter due to higher current period tax benefits (including
excess tax benefits of share-based compensation) and gain from the sale of certain minor brands.
For the nine months ended March 31, 2024, Corporate net sales decreased $203 million to $398 million due to a decrease in net sales of incidental businesses
managed at the corporate level. Corporate net earnings decreased $1.1 billion to a loss of $1.3 billion due primarily to the impairment charge of the Gillette
intangible asset.
LIQUIDITY & CAPITAL RESOURCES
Operating Activities
Operating cash flow was $14.1 billion fiscal year to date, an increase of $2.6 billion versus the prior year period. Net earnings, adjusted for non-cash items
(depreciation and amortization, intangible asset impairment, share-based compensation expense and deferred income taxes), generated $15.5 billion of
operating cash flow. Working capital and other impacts used $1.4 billion of cash in the period primarily driven by an increase in accounts receivable from sales
growth, a decrease in trade payables and a decrease in other liabilities. The decrease in trade payables resulted from reduced commodity costs, partially offset
by the impact of our supplier finance program (see Note 10, Supplier Finance Programs). The decrease in other liabilities is primarily driven by postretirement
benefit payments and the net periodic credit from other retiree benefits. Days sales outstanding increased by two days. Days inventory on hand increased by
three days.
Investing Activities
Investing activities used $3.0 billion of cash fiscal year to date primarily driven by capital expenditures and the settlement of net investment hedges.
Financing Activities
Financing activities used $12.4 billion of net cash fiscal year to date, mainly due to dividends to shareholders, treasury stock purchases and a net debt decrease,
partially offset by the impact of stock options and other.
As of March 31, 2024, our current liabilities exceeded current assets by $9.9 billion. We anticipate being able to support our short-term liquidity and operating
needs largely through cash generated from operations. We have strong short- and long-term debt ratings that have enabled and should continue to enable us to
refinance our debt as it becomes due at favorable rates in commercial paper and bond markets. In addition, we have agreements with a diverse group of
financial institutions that, if needed, should provide sufficient credit funding to meet short-term financing requirements.
MEASURES NOT DEFINED BY U.S. GAAP
In accordance with the SEC's Regulation S-K Item 10(e), the following provides definitions of the non-GAAP measures and the reconciliation to the most
closely related GAAP measure. We believe that these measures provide useful perspective on underlying business trends (i.e., trends excluding non-recurring
or unusual items) and results and provide a supplemental measure of period-to-period results. The non-GAAP measures described below are used by
management in making operating decisions, allocating financial resources and for business strategy purposes. These measures may be useful to investors, as
they provide supplemental information about business performance and provide investors a view of our business results through the eyes of management.
These measures are also used to evaluate senior management and are a factor in determining their at-risk compensation. These non-GAAP measures are not
intended to be considered by the user in place of the related GAAP measures but rather as supplemental information to our business results. These non-GAAP
measures may not be the same as similar measures used by other companies due to possible differences in method and in the items or events being adjusted.
Organic sales growth. Organic sales growth is a non-GAAP measure of sales growth excluding the impacts of acquisitions and divestitures and foreign
exchange from year-over-year comparisons. We believe this measure provides investors with a supplemental understanding of underlying sales trends by
providing sales growth on a consistent basis. This measure is used in assessing the achievement of management goals for at-risk compensation.

-- 28 of 39 --

The Procter & Gamble Company 27
The following table provides a numerical reconciliation of organic sales growth to reported net sales growth:
Three Months Ended March 31, 2024 	Net Sales Growth 	Foreign Exchange Impact
Acquisition & Divestiture
Impact/Other 	Organic Sales Growth
Beauty 	2 % 	3 % 	(2) % 	3 %
Grooming 	3 % 	7 % 	— % 	10 %
Health Care 	2 % 	1 % 	(1) % 	2 %
Fabric & Home Care 	2 % 	1 % 	— % 	3 %
Baby, Feminine & Family Care 	(2) % 	2 % 	— % 	— %
Total Company 	1 % 	2 % 	— % 	3 %
Acquisition & Divestiture Impact/Other includes the volume and mix impact of acquisitions and divestitures and rounding impacts necessary to reconcile net sales to
organic sales.
Nine Months Ended March 31, 2024 	Net Sales Growth 	Foreign Exchange Impact
Acquisition & Divestiture
Impact/Other 	Organic Sales Growth
Beauty 	2 % 	2 % 	(1) % 	3 %
Grooming 	5 % 	4 % 	— % 	9 %
Health Care 	6 % 	(1) % 	— % 	5 %
Fabric & Home Care 	5 % 	1 % 	— % 	6 %
Baby, Feminine & Family Care 	1 % 	2 % 	— % 	3 %
Total Company 	3 % 	1 % 	— % 	4 %
Acquisition & Divestiture Impact/Other includes the volume and mix impact of acquisitions and divestitures and rounding impacts necessary to reconcile net sales to
organic sales.
Adjusted free cash flow. Adjusted free cash flow is defined as operating cash flow less capital expenditures and excluding payments for the transitional tax
resulting from the U.S. Tax Act. Adjusted free cash flow represents the cash that the Company is able to generate after taking into account planned maintenance
and asset expansion. We view adjusted free cash flow as an important measure because it is one factor used in determining the amount of cash available for
dividends, share repurchases, acquisitions and other discretionary investments.
The following table provides a numerical reconciliation of adjusted free cash flow ($ millions):
Nine Months Ended March 31, 2024
Operating Cash Flow 	Capital Spending 	U.S. Tax Act Payments 	Adjusted Free Cash Flow
$ 	14,092 $ 	(2,539) $ 	422 $ 	11,975
Adjusted free cash flow productivity. Adjusted free cash flow productivity is defined as the ratio of adjusted free cash flow to net earnings excluding the
Gillette intangible asset impairment charge. We view adjusted free cash flow productivity as a useful measure to help investors understand P&G’s ability to
generate cash. Adjusted free cash flow productivity is used by management in making operating decisions, in allocating financial resources and for budget
planning purposes. This measure is also used in assessing the achievement of management goals for at-risk compensation.
The following table provides a numerical reconciliation of adjusted free cash flow productivity ($ millions):
Nine Months Ended March 31, 2024
Adjusted Free Cash Flow 	Net Earnings Adjustments to
Net Earnings Net Earnings
as Adjusted Adjusted Free Cash
Flow Productivity
$ 	11,975 $ 	11,830 $ 	1,026 $ 	12,856 	93 %
Adjustments to Net Earnings relate to the Gillette intangible asset impairment charge announced in December 2023.
(1)
(1)
(1)
(1)
(1)
(1)

-- 29 of 39 --

28 The Procter & Gamble Company
Core EPS. Core EPS is a measure of the Company's diluted EPS excluding items that are not judged by management to be part of the Company's sustainable
results or trends. Management views this non-GAAP measure as a useful supplemental measure of Company performance over time. This measure is also used
in assessing the achievement of management goals for at-risk compensation. The Core earnings measures included in the following reconciliation tables refer
to the equivalent GAAP measures adjusted as applicable for the following items:
• Incremental restructuring: The Company has historically had an ongoing level of restructuring activities of approximately $250 - $500 million before
tax. On December 5, 2023, the Company announced a limited market portfolio restructuring of its business operations, primarily in certain Enterprise
Markets, including Argentina and Nigeria. The adjustment to Core earnings includes the restructuring charges that exceed the normal, recurring level
of restructuring charges.
• Intangible asset impairment: As discussed in Note 4 to the Consolidated Financial Statements, the Company recognized in the three months ended
December 31, 2023, a non-cash, after-tax impairment charge of $1.0 billion ($1.3 billion before tax) to adjust the carrying value of the Gillette
intangible asset acquired as part of the Company's 2005 acquisition of The Gillette Company.
We do not view the above items to be part of our sustainable results, and their exclusion from core earnings measures provides a more comparable measure of
year-on-year results. These items are also excluded when evaluating senior management in determining their at-risk compensation.
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
Reconciliation of Non-GAAP Measures
Three Months Ended March 31, 2024 	Three Months Ended
March 31, 2023
Amounts in millions except per share amounts 	As Reported (GAAP) Incremental
Restructuring Intangible
Impairment Core
(Non-GAAP) As Reported
(GAAP)
Cost of products sold 	$ 	9,855 	$ 	(13) $ 	— $ 	9,842 $ 	10,404
Selling, general and administrative expense 	5,880 	3 	— 	5,883 	5,416
Operating income 	4,460 	10 	— 	4,471 	4,248
Income taxes 	812 	— 	— 	812 	864
Net earnings attributable to P&G 	3,754 	10 	— 	3,763 	3,397
Core EPS
Diluted net earnings per common share 	$ 	1.52 	$ 	— $ 	— $ 	1.52 $ 	1.37
For the three months ended March 31, 2023, there were no adjustments to or reconciling items for Core EPS.
Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.
CHANGE VERSUS YEAR AGO
Net earnings attributable to P&G 	11 %
Core net earnings attributable to P&G 	11 %
Diluted net earnings per common share 	11 %
Core EPS 	11 %
(1)
(2)
(1)
(2)

-- 30 of 39 --

The Procter & Gamble Company 29
THE PROCTER & GAMBLE COMPANY AND SUBSIDIARIES
Reconciliation of Non-GAAP Measures
Nine Months Ended March 31, 2024 	Nine Months Ended March
31, 2023
Amounts in millions except per share amounts 	As Reported (GAAP)
Incremental
Restructuring
Intangible
Impairment
Core
(Non-GAAP)
As Reported
(GAAP)
Cost of products sold 	$ 	30,500 	$ 	(25) $ 	— $ 	30,475 $ 	32,147
Selling, general and administrative expense 	17,006 	(4) 	— 	17,002 	15,334
Operating income 	14,660 	29 	1,341 	16,031 	13,972
Income taxes 	3,061 	(20) 	315 	3,357 	2,774
Net earnings attributable to P&G 	11,742 	49 	1,026 	12,817 	11,269
Core EPS
Diluted net earnings per common share 	$ 	4.75 	$ 	0.02 $ 	0.42 $ 	5.19 $ 	4.53
For the nine months ended March 31, 2023, there were no adjustments to or reconciling items for Core EPS.
Diluted net earnings per common share are calculated on Net earnings attributable to Procter & Gamble.
CHANGE VERSUS YEAR AGO
Net earnings attributable to P&G 	4 %
Core net earnings attributable to P&G 	14 %
Diluted net earnings per common share 	5 %
Core EPS 	15 %
Item 3. 	Quantitative and Qualitative Disclosures About Market Risk
There have been no material changes in the Company’s exposure to market risk since June 30, 2023. Additional information can be found in Note 9, Risk
Management Activities and Fair Value Measurements, of the Company's Form 10-K for the fiscal year ended June 30, 2023.
Item 4. 	Controls and Procedures
Evaluation of Disclosure Controls and Procedures
The Company’s Chairman of the Board, President and Chief Executive Officer, Jon R. Moeller, and the Company’s Chief Financial Officer, Andre Schulten,
performed an evaluation of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of
1934 (Exchange Act)) as of the end of the period covered by this report.
Messrs. Moeller and Schulten have concluded that the Company’s disclosure controls and procedures were effective to ensure that information required to be
disclosed in reports we file or submit under the Exchange Act is (1) recorded, processed, summarized and reported within the time periods specified in SEC
rules and forms, and (2) accumulated and communicated to our management, including Messrs. Moeller and Schulten, to allow their timely decisions regarding
required disclosure.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting that occurred during the Company’s fiscal quarter ended March 31, 2024, that have
materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. 	Legal Proceedings
The Company is subject, from time to time, to certain legal proceedings and claims arising out of our business, which cover a wide range of matters, including
antitrust and trade regulation, product liability, advertising, contracts, environmental issues, patent and trademark matters, labor and employment matters and
tax. In addition, SEC regulations require that we disclose certain environmental proceedings arising under Federal, State or local law when a governmental
authority is a party and such proceeding involves potential monetary sanctions that the Company reasonably believes will exceed a certain threshold ($1
million or more).
There were no material changes during the quarter ended March 31, 2024, to our disclosure in Part II, Item 1, “Legal Proceedings” of our Form 10-Q for the
quarter ended December 31, 2023. There are no other relevant matters to disclose under this Item for this period.
(1)
(2)
(1)
(2)

-- 31 of 39 --

30 The Procter & Gamble Company
Item 1A. 	Risk Factors
For information on risk factors, please refer to "Risk Factors" in Part I, Item 1A of the Company's Form 10-K for the fiscal year ended June 30, 2023.
Item 2. 	Unregistered Sales of Equity Securities, Use of Proceeds and Issuer Purchases of Equity Securities
ISSUER PURCHASES OF EQUITY SECURITIES
Period
Total Number of
Shares Purchased
Average Price Paid per
Share
Total Number of Shares Purchased as Part
of Publicly Announced Plans or Programs
Approximate Dollar Value of Shares That May
Yet Be Purchased Under Our Share Repurchase
Program
1/01/2024 - 1/31/2024 	— 	— 	—
2/01/2024 - 2/29/2024 	3,156,831 	$158.39 	3,156,831
3/01/2024 - 3/31/2024 	3,107,656 	160.89 	3,107,656
Total 	6,264,487 	$159.63 	6,264,487
All transactions are reported on a trade date basis and were made in the open market with large financial institutions. This table excludes shares withheld from employees to
satisfy tax withholding requirements on option exercises and other equity-based transactions. The Company administers cashless exercises through an independent third
party and does not repurchase stock in connection with cashless exercises.
Average price paid per share for open market transactions excludes commission.
In accordance with the repurchase program announced on July 28, 2023, the Company reaffirmed in its earnings release on April 19, 2024, that it expects to reduce
outstanding shares through direct share repurchases at a value of $5 to $6 billion in fiscal year 2024, notwithstanding any purchases under the Company's compensation and
benefit plans. Purchases may be made in the open market and/or private transactions and purchases may be increased, decreased or discontinued at any time without prior
notice. The share repurchases are authorized pursuant to a resolution issued by the Company's Board of Directors and are expected to be financed by a combination of
operating cash flows and issuance of debt.
Item 5. 	Other Information
During the three months ended March 31, 2024, none of our directors or officers adopted or terminated a "Rule 10b5-1 trading arrangement" or "non-Rule
10b5-1 trading arrangement" as defined in Item 408 of Regulation S-K.
(1) 	(2) 	(3)
(3)
(3)
(3)
(1)
(2)
(3)

-- 32 of 39 --

The Procter & Gamble Company 31
Item 6. 	Exhibits
3.1 Amended Articles of Incorporation (as amended by shareholders at the annual meeting on October 11, 2011 and consolidated by the
Board of Directors on April 8, 2016) (Incorporated by reference to Exhibit (3-1) of the Company's Form 10-K for the year ended June
30, 2016)
3.2 Regulations (as approved by the Board of Directors on December 13, 2022, pursuant to authority granted by shareholders at the annual
meeting on October 13, 2009) (Incorporated by reference to Exhibit (3-2) of the Company’s Current Report on Form 8-K filed
December 13, 2022)
4.1 Indenture, dated as of September 3, 2009, between the Company and Deutsche Bank Trust Company Americas, as Trustee (Incorporated
by reference to Exhibit (4-1) of the Company's Annual Report on Form 10-K for the year ended June 30, 2015)
10.1 Summary of Additional Personal Benefits Available to Certain Officers and Non-Employee Directors* +
31.1 Rule 13a-14(a)/15d-14(a) Certification – Chief Executive Officer +
31.2 Rule 13a-14(a)/15d-14(a) Certification – Chief Financial Officer +
32.1 Section 1350 Certifications – Chief Executive Officer +
32.2 Section 1350 Certifications – Chief Financial Officer +
101.SCH 	Inline XBRL Taxonomy Extension Schema Document
101.CAL 	Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF 	Inline XBRL Taxonomy Definition Linkbase Document
101.LAB 	Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE 	Inline XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)
* Compensatory plan or arrangement
+ Filed herewith
Pursuant to Rule 406T of Regulation S-T, this information is furnished and not filed for purposes of Sections 11 or 12 of the Securities Act of 1933 and
Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned
thereunto duly authorized.
THE PROCTER & GAMBLE COMPANY
April 19, 2024 	/s/ MATTHEW W. JANZARUK
Date 	(Matthew W. Janzaruk)
Senior Vice President - Chief Accounting Officer
(Principal Accounting Officer)
(1)
(1)
(1)
(1)
(1)
(1)

-- 33 of 39 --

Exhibit (10.1)
Summary of Additional Personal Benefits Available to Certain Officers and Non-
Employee Directors
ADDITIONAL PROGRAMS AVAILABLE TO CERTAIN OFFICERS AND
NON-EMPLOYEE DIRECTORS
I. Certain Officer Programs
The following is a summary of programs that are available to employees at the President level or higher ("Eligible Employees").
Financial Counseling
The Financial Counseling Program is designed to address the special tax, estate, and financial planning needs of Eligible Employees. The Company will contract
with a standard provider for these services. Employees will be taxed on the benefit value of these services. The Company will not provide any tax gross-ups
for these services.
Execuve Officers who parcipated in the prior annual spend program may connue to elect to receive the annual spend. Under the prior program, the
Company provides an annual $8,500 spend upon confirmaon from each parcipant that a tax or financial planning service has been retained in the current
calendar year.
Execuve Physical
The Company will provide an annual physical offered at a Company-approved health facility in Cincinna or via an MDVIP physician if the execuve is located
near an MDVIP provider.
Personal Security
The Company provides personal security services such as home security systems/monitoring and secured workplace parking to the Execuve Chairman and
Chief Execuve Officer at Company expense. In addion, the Chief Human Resources Officer may approve personal security services to other Company
Employees where appropriate, again at Company expense.
Spouse and Personal Travel
The Company pays for reasonable air and ground transportaon, other incidental costs plus sightseeing tours and similar acvies when applicable, when
spouses (or significant others) accompany employees for business purposes. Business purpose is established and approved by the Chief Human Resources
Officer, for example in circumstances where there is a need to familiarize the spouse with business issues and demands facing employees, or to meet other
P&G employees and spouses.
While Company aircra is generally used for Company business only, for security reasons the Execuve Chairman and Chief Execuve Officer are required to
use Company aircra for all air travel, including personal travel and travel to outside board meengs. While traveling on Company aircra, the Execuve
Chairman or Chief Execuve Officer may bring a limited number of guests to accompany them. If a Company aircra flight is already scheduled for business
purposes and can accommodate addional passengers, the Chief Financial Officer and the Vice Chairs of the Company may use the aircra for personal travel
and guest accompaniment including travel to outside board meengs where the other company cannot provide transportaon. Outside boards typically
provide some level of reimbursement to the Company for these trips. To the extent personal travel results in imputed income to the execuve, the Company
does not provide gross-up payments to cover the execuve's personal income tax due on such imputed income.
Limited Local Transportaon
To increase efficiency, Eligible Employees are provided limited local transportaon within Cincinna.

-- 34 of 39 --

II. Non-Employee Director Programs
This paragraph summarizes a travel program available to spouses, significant others and family members (collecvely, "Guests") who accompany non-
employee directors ("Directors"). The purpose of this program is to familiarize the Guests with the business issues and demands facing the Directors and to
meet other Guests.
Generally, Guests are permied to accompany Directors to regular Board meengs and other Board acvies, so long as the Director is using Company
aircra and the Guests do not cause incremental aircra costs. In addion, Directors are encouraged to bring a Guest to two Board meengs each year. With
respect to these meengs, the Guests' travel costs may be incremental and/or may involve commercial flights. The Company pays for these costs and
arranges and pays for sightseeing tours and similar acvies and other incidental costs for Directors and Guests, while Directors aend both regular and off-
site Board meengs.

-- 35 of 39 --

EXHIBIT 31.1
Rule 13a-14(a)/15d-14(a) Certifications
I, Jon R. Moeller, certify that:
(1) I have reviewed this quarterly report on Form 10-Q of The Procter & Gamble Company;
(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
(4) The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-
15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over financial reporting; and
(5) The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal
control over financial reporting.
/s/ JON R. MOELLER
(Jon R. Moeller)
Chairman of the Board, President and Chief Executive Officer
April 19, 2024
Date

-- 36 of 39 --

EXHIBIT 31.2
Rule 13a-14(a)/15d-14(a) Certifications
I, Andre Schulten, certify that:
(1) I have reviewed this quarterly report on Form 10-Q of The Procter & Gamble Company;
(2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this
report;
(3) Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
(4) The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-
15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those
entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for
external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent
fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over financial reporting; and
(5) The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal
control over financial reporting.
/s/ ANDRE SCHULTEN
(Andre Schulten)
Chief Financial Officer
April 19, 2024
Date

-- 37 of 39 --

EXHIBIT 32.1
Section 1350 Certifications
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of The Procter & Gamble
Company (the “Company”) certifies to his knowledge that:
(1) The Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2024 fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in that Form 10-Q fairly presents, in all material respects, the financial conditions and results of operations of the
Company.
/s/ JON R. MOELLER
(Jon R. Moeller)
Chairman of the Board, President and Chief Executive Officer
April 19, 2024
Date
A signed original of this written statement required by Section 906 has been provided to The Procter & Gamble Company and will be retained by The Procter
& Gamble Company and furnished to the Securities and Exchange Commission or its staff upon request.

-- 38 of 39 --

EXHIBIT 32.2
Section 1350 Certifications
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of The Procter & Gamble
Company (the “Company”) certifies to his knowledge that:
(1) The Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2024 fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in that Form 10-Q fairly presents, in all material respects, the financial conditions and results of operations of the
Company.
/s/ ANDRE SCHULTEN
(Andre Schulten)
Chief Financial Officer
April 19, 2024
Date
A signed original of this written statement required by Section 906 has been provided to The Procter & Gamble Company and will be retained by The Procter
& Gamble Company and furnished to the Securities and Exchange Commission or its staff upon request.

-- 39 of 39 --